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Brand-name drug costs continue to create a burden for many US seniors who receive care 
from healthcare institutions. Generic medication is as therapeutic as is brand-name drugs 
and, in most cases, costs far less. Despite this cost difference, physicians continue to 
prescribe brand-name drugs. The purpose of this cross-sectional study was to explore 
physicians’ patterns of prescribing brand-name drugs over generic drugs. This study was 
guided by the medical home model, which was developed in 1967 by the American 
Academy of Pediatrics. The study incorporated a purposeful sampling approach with a 
sample size of 151 physicians. Multiple linear regression was used to examine the 
associations between cost of treatment using generic medications and determinants of 
physicians’ pattern of prescribing brand-name medications over generic medications. 
There were no statistically significant associations between physician belief of cost using 
generic medications and determinants of physicians’ pattern of prescribing brand-name 
medications over generic medications, suggesting that physicians’ prescription patterns 
are not solely determined by cost of the drug to the patients. The positive social change 
implication of this study is in the awareness that it generates among physicians, with 
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Chapter 1: Introduction to the Study 
 
Introduction   
The cost of prescription drugs is too high for many in the United States. Because 
of the high cost of prescription drugs, more people in the United States, including 
children, are going without needed medications. According to Felland and Reshovsky 
(2009), many people in the United States cannot fill their prescriptions due to the high 
cost, and less favorable prescription drug coverage may also contribute to the high rate of 
unfilled prescriptions. The most vulnerable individuals who continue to face these 
challenges are the elderly, those with low income, and individuals without insurance 
(Felland & Reshovsky, 2009). The cost of prescription drugs has become a policy issue 
for the Medicare and Medicaid programs. At the state level, the debate has been driven 
by increased Medicaid drug spending. Despite the issue of prescription drug cost, 
researchers have not examined why physicians will not prescribe generic prescription 
drugs when such equivalent generic brands exist. 
The number of people in the Unites States under the age of 65 who were having 
problems filling their prescriptions due to the high cost of prescription drugs was steady 
in the early decade, but this trend changed. For example, the number of individuals 
younger than 65 years of age who cannot afford their medication due cost grew from 
10.3% in 2003 to 13.9% in 2007 for all (Felland & Reshovsky, 2009). About  36 million 
people in the United States between the ages of 19 and 64 went without prescription 
drugs because of cost in 2007; this was an increase of 11.7 million compared to 2003, and 





2003 through 2007 (Felland & Reshovsky, 2009). Medication under-usage was also a 
common reported problem among the elderly with chronic health conditions such as 
asthma, heart failure, hypertension, high cholesterol, depression, and diabetes (Piette, 
Heister, & Wagner, 2004). Because children more likely to be in better health compared 
to their elderly counterparts, they require fewer medications and have less prescription 
access problems; however, unmet prescription medication needs grew between 2003 and 
2007 from 3.1% to 5% (Felland & Reshovsky, 2009). It is possible that the increase in 
prescription drug nonaffordability was a result of higher prescription drug cost, increased 
use of brand-name drugs, and physicians not prescribing generic drugs. Furthermore, it 
could be a result of drug prices rising faster than individual earnings and the introduction 
of newer and more expensive medications in the marketplace.  
The Medicare Modernization Act (MMA, 2003) is a voluntary program that helps 
pay for prescription drugs through a private plan that is approved by the federal 
government. According the Center for Medicare and Medicaid Services (CMC), there are 
about 49 million individuals who have access to Medicare drug benefit programs [CMS], 
2011). Public programs such as Medicare and Medicaid play a role in helping individuals 
pay for their health care including prescription drugs, but continued increases in 
prescription drug costs may make the program nonviable. There is also public concern 
about the future of the prescription drug benefit program, particularly in light of the new 
healthcare policy passed into law by the Obama administration, according to the 
Congressional Budget Office [CBO], 2014). Seniors continue to be the largest users of 





Meanwhile, use of medications by people 19- to 25-years old went down. This change in 
per-capita prescription drug use could be a result of better disease management or a trend 
in self-rationing by patients, which could contribute negatively or positively to the future 
healthcare costs in the US, according to Management Information System [MIS] (2011). 
Problem Statement   
Medication serves as a therapeutic intervention designed to manage both acute 
and chronic health conditions. People in the United States who suffer from multiple 
health conditions may depend on several medications to manage their health. Currently, 
Medicare and Medicaid provide healthcare benefit for seniors through paying for some of 
their healthcare costs including prescription drugs. However, out-of-pocket costs, higher 
costs of prescription drugs, and the recent Medicare and Medicaid benefit reduction may 
reduce the ability of seniors to meet this extra cost. Nursing homes may experience 
difficulties in providing adequate care for their residents (CMS, 2012).The Health System 
Change (HSC, 2003) revealed that many seniors in nursing homes take more than one 
prescription drug to manage their chronic health conditions. According to Klein, Turvey, 
and Wallace (2004), the elderly sometimes delay refilling their prescriptions due to high 
costs. Being unable to refill a prescription could result in the individual not following 
their medication regimen, which in turn can lead to further health problems and even 
hospitalizations.  
Chronic health conditions such as diabetes, hypertension, high cholesterol levels, 
asthma, and depression require medications (Wood, 2012). According to Wood (2012), 





to 33% to 69% of patients, the lack of medication compliance has resulted in up to 
125,000 deaths per year in the United States . Cardiovascular disease is a chronic 
condition associated with hypertension. In 2001, some 89,000 deaths would have 
occurred among patients age 40 and older if blood pressure medications were not taken 
(Wood, 2012). Patients who are diabetic are less likely to die prematurely if they adhere 
to their medication regimen, and those who suffer from asthma are 11% less likely to 
visit the emergency room (ER) or be hospitalized (Wood, 2012).  
The New England Healthcare Institute (NEHI, 2009) reported that medication 
noncompliance leads to a waste of dollars in the healthcare system. The NEHI further 
revealed that most people in the United States do not take their medication as prescribed; 
the resultant effect is an additional $100 billion yearly hospitalization costs, and the 
barriers to medication compliance include the cost of prescription drugs (NEHI, 2009). 
There is a correlation between poor health outcomes and patients who do not take their 
medication as prescribed by their physicians. Among diabetic and heart-disease patients, 
those who do not take their medication as prescribed had a higher mortality rate, 12.1% 
versus 6.7% (NEHI, 2009). Additionally, among those who suffer from diabetes, 
hypertension, high cholesterol levels, and poor heart conditions, the rate of 
hospitalization is higher compared to those who take their medication as prescribed. In 
addition, because 75% of US healthcare costs are tied to chronic disease due to 
medication noncompliance, high prescription drug costs is a potential drawback to 





Prescription drug spending continues to increase. In 2001, the cost of prescription 
drugs in United State was $141 billion. Because seniors depend on Medicare prescription 
benefit programs to offset some of their prescription drug costs, containing drug costs 
could help to stabilize the Medicare program (Haas, Phillips, Gerstenberger, & Seger, 
2005). 
In 2007, yearly prescription drug costs in the United States reached $286 billion 
(Paul et al., 2010). Generic drugs cost less when compared to brand-name drugs, so an 
increased use of generic drugs could result in healthcare savings and serve as a cost-
cutting strategy for nursing homes suffering from Medicare and Medicaid cuts. Several 
expensive drugs will go off patent between 2010 and 2014. This will result in $209 
billion yearly sale. If this trend continues, brand-name drug sales will see a further 
reduction in yearly sales (Paul et al., 2010). Increasing or improving generic prescription 
rates and reducing the sale of brand-name drugs can reduce healthcare costs and prevent 
nursing homes from falling short in their revenues. 
According to the Robert Wood Johnson Foundation (1996), chronic conditions 
are the major cause of death among people in the United States, and almost 100 million 
people in the United States suffer from some form of chronic health issue. It is projected 
that by 2040, an estimated 160 million people in the United States will have a chronic 
condition. The Robert Wood Johnson Foundation further revealed that the cost for caring 
for people in the United States with chronic condition was $470 billion in 1995, and by 
the year 2040, that cost is estimated to be $864 billion. According to Anderson (2004), in 





disease, cancers, stroke, diabetes, mental illness, Alzheimer’s, kidney disease, and 
respiratory diseases). In addition, 90% of seniors in the United States suffer from one 
chronic disease, and 77% suffer from more than one chronic condition. According to 
Mendelson, Ramchand, Abramson, and Tumlinson (2002), in 2002, nursing homes 
residents received an average of 6.7 routing prescription drugs daily, with an additional 
2.7 as-needed medications.   
The cost of medications used to treat chronic conditions has social and economic 
implications. For example, in 2008 one in five hospital admissions was a result of 
diabetes, with total cost of $83 billion. Hospital stays of individuals with diabetes are 
longer when compared to those without diabetes. Medicare covered 60% of the diabetes 
cost, private insurance covered 23%, and the rest was covered by private payments 
(Fraze, Jiang, & Burges, 2008). 
Currently, state Medicaid programs provide healthcare services for people with 
low incomes, long-term care for the older population and for individuals with disabilities. 
As more chronic conditions become apparent, more people will need healthcare services, 
and more will qualify for Medicaid benefits. In the state of North Carolina, there has been 
an increase in the older population, with people having more chronic diseases.  But  with 
recent Medicare and Medicaid budget cuts, there a need for new strategies in order for the 
state to improve the quality of healthcare services and decrease healthcare costs (Kaiser 
Health News [KHN], (2014)]. Medicare and Medicaid provide benefits for seniors to pay 
for some of their healthcare costs, including prescription drugs. Any remaining balance is 





The HSC (2003) revealed that many seniors take more than one prescription drug to 
manage their chronic health conditions. The high costs of prescription drugs could eat 
deeply into their low incomes and may prevent them from paying their Medicare and 
Medicaid out-of-pocket costs including refilling their prescriptions (Strickland & Hanson, 
1996). Nursing homes are revenue-driven organizations, and when residents run out of 
money, two things may happen: they may be asked to go home without completing their 
stay, or they may not have enough money to pay for their prescription drugs. 
For example, paracetamol is a chemical ingredient found in brand-name 
painkillers, but it is also sold as a generic drug. The Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) agreement does not prevent governments from requiring 
accurate labeling or allowing generic substitution. Competition between drug companies 
and generic producers has been more effective than negotiations with drug companies in 
reducing the cost of drugs. The price of an average generic drug is 75% less than a brand-
name prescription drug (CBO, 2010).  
The National Health Expenditure Accounts (NHEA) revealed that healthcare 
spending reached $2.6 trillion in 2010. This is about $8,402 per person, and it is 18% of 
the U.S. gross domestic product (CMS, 2012).The U.S government financed 29% of 
healthcare costs in 2010, an increase from 23% in 2007. The NHEA also reported that 
average yearly healthcare costs are expected to grow from 6.2% through 2018, a number 
that surpasses the anticipated overall economic growth for the period of 4.1%. By 2018, it 





growth rate, in 15 years, healthcare costs will amount to 50% of U.S. GDP.  The question 
becomes whether or not the U.S. economy is sustainable with this amount of expenditure.  
Prescription drugs are dispensed in hospitals, including long-term care facilities, 
for the management of chronic diseases. Based on increasing healthcare costs, the use of 
cheaper generic prescription drugs will hold down the growth of healthcare costs 
nationally and across institutional settings such as hospitals and long-term care facilities. 
The use of generic drugs saved the U.S. healthcare system about $1.07 trillion from 2002 
through 2011, with $192.8 billion in savings in 2011 alone (CMS, 2012). Knowing that 
the U.S. government’s share of healthcare spending will soon reach 30% and as the oldest 
Baby Boomers become eligible for government-sponsored programs such as Medicare, 
the increased use of generic prescription drugs is critical ensuring Medicare and Medicaid 
sustainability (CBO, 2010).  
Researchers have identified cost-saving approaches from various studies, 
estimates that result because of the use of generic drug, and generic and therapeutic 
substitutions. Other scholars have examined savings to the U.S. healthcare system and 
savings from program implementations (CBO, 2010; Haas et al., 2005; Scott & 
O’Donnell, 2007). The Generic Pharmaceutical Association (GPhA) estimated the 
amount paid on generic drugs and brand-name drugs for the year 1999 through 2010 and 
found that generic substitution saved the U.S. healthcare system about $1 trillion. In 2010 
alone generic substitutions saved the U.S. healthcare system more than $157 billion 





generic drugs in the Medicare Part D prescription drug program and found that it resulted 
in a cost saving of $33 billion in 2007.  
The CBO (2010) evaluated additional savings from generic and therapeutic 
substitutions and found that an increase in generic substitutions at the rate of 100% would 
have resulted in cost savings at about $900 billion and an additional cost savings of $4 
billion in therapeutic substitutions in 2007. Scott and O’Donnell (2007) analyzed cost 
savings through program implementation in a managed-care organization in the form of 
physician participation in 2005 and 2006 and found that after program costs, the 
organization saved $397,486 in 2005 and $453,545 in 2006. Dobscha, Winterbottom, and 
Snodgrass (2007) conducted a study for the Department of Veterans Affairs (VA) 
hospital and found potential savings through program implementation of promoting the 
use of generic antidepressants over brand-name medications. From March of 2002 
through August, the policy resulted in a net saving of $2.5 billion (Dobscha et al., 2007). 
Two scholars used data regarding claims from 45 private health insurance 
organizations from 2003 through 2007 to compare the cost of health care in individuals 
using selective serotonin reuptake inhibitors ( SSRI) when therapeutic substitution  
occurs midtreament. Wu et al. (2011) found that patients who switched from brand-name 
drugs to generic drugs had higher rates of hospitalization due to switching in 
midtreatment. The switch also result in healthcare cost savings of $881 dollars (Wu et al., 
2011). Viahiotis, Devine, Eicholz, and Kautzner (2011) used claim data from 2005 to 
2007and compared healthcare costs of using brand-name drugs versus generic drugs in 





SSRIs was significantly lower when compared to brand-name medications (the average 
was $3,660 and $4,587, respectively) (Viahiotis et al., 2011).           
Significance   
Concerns have been raised about the rise in prescription drug spending, the cost of 
diabetes, and Medicare and Medicaid expenditures. These factors influence Medicare and 
Medicaid spending with respect to hospital and nursing home funding. Nursing home 
expenditures are a financial burden for those who receive treatment, and particularly for 
those who are not covered by Medicare and Medicaid. The CBO (2010) reported that in 
2007, dispensing generic drugs rather than brand-name drugs reduced prescription drug 
costs by $33 billion. The American Diabetes Association (ADA, 2013) revealed that in 
2012, the total estimated cost of diagnosed diabetes was $245 billion, including $176 
billion in direct medical costs and losses to productivity of $69 billion. In patients with a 
chronic medical condition such as Type 2 diabetes, intensive blood glucose control with 
prescription drugs may decrease the progression of microvascular disease and prevent 
heart attacks. However, the cost of prescription drugs may inhibit this treatment (ADA, 
2013). 
Generic prescription drugs are therapeutic and serve the same purpose as brand-
name drugs, but they are less expensive when compared to brand-name drugs. The 
United States Food and Drug Administration examines generic drug formulation and if it 
finds them to be suitable, will approve them as therapeutically equivalent to brand-name 
drugs in terms of safety, strength, and quality (as cited in Haas et al., 2005). Substituting 





the drug-consuming population (Haas et al., 2005). Due to the rising cost of healthcare 
stemming in part from the cost of prescription drugs and the cost of managing chronic 
health conditions, healthcare policy makers can no longer ignore….Many depend on 
Medicare and Medicaid for healthcare services, and sustaining these social programs is 
critical in addressing healthcare costs. The increased use of generic prescription drugs 
through physician automation generic prescription is critical to ensuring Medicare and 
Medicaid sustainability. 
The results of this study can lead to positive significant social change by 
providing patient education on potential savings from generic medication and by 
providing information on how generic drugs are cheaper and are therapeutically 
equivalent as brand-name drugs. The time required for generic entry into the U.S. market 
is too long. This has a significant negative implications on pharmaceutical expenditure. 
The knowledge gained from this study can be used to reverse this trend. The use of 
generic drugs is a policy option that will allow for access to affordable drugs. The 
knowledge gained from this study can also be used to address negative perceptions of 
generic drugs. If patients have a positive perception of generic drugs, they may be 
prompted to use more generic drugs or to ask their physicians to prescribe generic drugs, 
making it easier for them to afford to pay for their medication. Through generic 
substitution savings, more money will be available to increase the primary prevention 
aspects of care. Finally, this study will provide policy makers with relevant information 





challenge to seniors, the information gained from this study can serve as a strategic tool 
in the area of generic cost savings. 
Purpose of the Study    
This study used a quantitative research approach. The purpose of this study was to 
address the behavior of primary care physicians regarding the prescribing of generic and 
brand-name drugs for the treatment of chronic conditions in the state of North Carolina. 
Although government programs such as Medicare and Medicaid provide health benefits 
to millions of people in the United States, including prescription drug benefits, recent 
cuts in these programs and the cost of prescription drugs continue to impact beneficiaries 
of these programs, including those in North Carolina (KHN, 2014). 
Theoretical Framework    
The theoretical framework of this study was based on the medical home model 
concept that was presented in 1967 by the American Academy of Pediatrics. The medical 
home model is characterized by the availability of a personal physician for every 
family/patient. The delivery of first-contact care is ensured by the physician in this 
model. Understanding of the needs of the family/patient and facilitation of 
comanagement that is planned throughout the individual’s lifespan is also made certain 
by the physician. The physician must have the capacity and resources to fulfill the needs 
of the family/patient (Health Policy Brief, 2010).  
 The basis of this model resides in the delivery of patient-centered care that 
involves a team-based approach for facilitating a complete range of healthcare services. 





acute care, mental and behavioral health care, end-of-life care, and preventive services. It 
also involves the coordination and integration of care that is not delivered by the Patient-
Centered Medical Home Model (PCMH) across the multifaceted healthcare system and 
patient community. The emphasis of this model is on the reduction of the costs of care by 
improving access to vigorous primary care. The medical home model presents a way to 
improve health care in the United States through the transformation of the process of 
organization and delivery of primary care, according to Consumer Assessment of 
Healthcare Providers and System (CAHPS, 2011). This framework is of value for the 
provision of care by primary care physicians practicing in Raleigh, North Carolina. It 
forms the basis for the prescription of appropriate drugs that can be more affordable in 
order to ensure that the population is receiving adequate care in accordance with the 
guidelines of the medical home model concept.  
 This theoretical framework was selected because it provides an approach towards 
integrative health care that, in this model, is based on one main point of access. Most of 
the healthcare systems in the United States are using this model of health care for 
providing services to patients. Data can be retrieved through this model regarding the 
prescribing practices of primary care physicians in the state of North Carolina. Several 
scholars have used this model (Henderson, Princell, & Martin, 2012; Jaudes et al., 2011). 
Lee et al. (2011) used this model to determine the possibility of eliminating disparities in 
health care that are encountered by minorities in accessing healthcare services. Windel, 
Anderko, and Konetzka (2011) claimed that this model can be employed for shared 





prescription of drugs. Shared decision making ability permits the patient to be involved in 
selecting the most appropriate type of drug that is best from all aspects. This model can 
also curb the cost of health care through the use of medicines that are preventative and 
cost effective (Marshall et al., 2011). Therefore, this model was used as a theoretical 
framework in this study because it can facilitate the use of generic medicines.     
The medical home model can also be applicable to the healthcare needs of seniors 
residing in nursing homes. Just as geography, transportation, and financial barriers impact 
children, these barriers also affect seniors in nursing homes across the United States. The 
model is designed so that patients, including seniors in nursing homes, get care when and 
where they need it (National Committee for Quality Assurance [NCQA], 2011). Using 
the medical home model provides a template for providing care for seniors residing in 
nursing homes in North Carolina. 
Research Question   
This study included the following  research question:  
1. What factors influence physicians’ patterns of prescription of brand-name 
medications over generic medications? 
Hypotheses   
H1: Brand popularity and its therapeutic effect do not influence prescribing 
behavior of brand-name medications over generic medications.  
H0: Brand popularity and its therapeutic effect do influence prescribing behavior 





Nature of the Study   
This study was quantitative in nature. I examined the behavior of physicians 
regarding the prescribing of generic and brand-name drugs for the treatment of chronic 
conditions in North Carolina. 
Study Limitations   
 There were several limitations associated with this study. First, I was required to 
conduct the surveys in a predetermined period of time. Second, the sample of the study 
included only the population of North Carolina. Therefore, the results of this research 
were representative of only a specific region and might not be applicable to the entire 
population of the United States. The sample size of the study was also a limitation 
because it was too small to represent the practices of all the general practitioners 
regarding the prescription of generic and brand-name drugs. Another limitation of this 
research was the method of data collection in that an online survey was used. This 
method did not produce a large enough sample size. This can cause difficulties in the 
statistical analysis of the data. Quantitative studies using a statistical analysis method 
require a large sample size to provide valid results. Based on this fact, there will be a 
need for further research with a larger sample size to ensure the development of valid 
results.  
Summary   
 The cost of prescription drugs poses a challenge for millions of people in the 
United States, and also presents a cost-control challenge for private and public health 





United States are going without prescribed drugs. According to Felland and Reshovsky 
(2009), one in seven individuals under the age of 65 in the US was not able to fill their 
prescription drug as a result of cost. The high cost of medication and less favorable 
prescription drug programs may contribute to the high rate of unfilled prescriptions. The 
elderly are the most vulnerable individuals who continue to face these challenges because 
most of them lack insurance and are on low or fixed incomes (Felland & Reshovsky, 
2009). Several researchers (CBO, 2010; Haas et al., 2005; Scott & O’Donnell, 2007) 
indicated that generic drugs are therapeutic and cost far less when compared brand-name 
drugs, and significant cost savings can result with increased use of generic medications. 
Reports also indicate that the elderly delay refilling their prescriptions due to cost. 
The elderly saw their prescription drug cost jump from $28.50 in 1992 to $42.30 in 2000 
while the number of prescriptions written is steadily increasing (Korn, Reichert, Simon, 
& Halm, 2003).The impact of not being able to refill prescription drugs as a result of  
cost  could lead to non-medication compliant. Medication noncompliance has been 
shown to result in repeat hospitals visits.  In 2001, the cost of prescription drugs in the 
United States was $141 billion. Since seniors depend on social programs such as the 
Medicare prescription benefit to offset some of their prescription drug costs, containing 
drug spending costs could stabilize the Medicare program.  There is a need for educating 
patients, healthcare professionals, policy makers, and physicians to make them more 
aware that greater prescription of generic drugs can save money. Chapter 2 will focus on 
the literature review, a brief history of Medicare and Medicaid, brand-name drugs versus 















Chapter 2: Literature Review   
Introduction   
The rise in prescription drug costs, particularly for brand-name prescription drugs, 
is concerning to many people in the United States, including private and public health 
institutions. This cost is a central policy issue for the Medicare and Medicaid programs. 
At the state level, the debate has been driven by increases in Medicaid drug spending. 
Despite the continued rise in prescription drug costs, little research has been conducted 
concerning why physicians will not automatically prescribe generic drugs considering the 
relative low cost of generic medication as compared to brand-name prescription drugs. 
State awareness of prescription drug spending in nursing homes has also increased as 
budget challenges force Medicaid cost-containment strategies. At the same time, the 
elderly population is increasing in the United States, and this growing population has 
chronic health conditions. Most of this older population depends on nursing homes for 
their healthcare needs (Mendelson et al., 2002). In 1997, for example, there were about 
1.6 million residents in 17,000 nursing homes across the United States (author, year). 
This number will continue to increase as a result of the growing older population 
(Mendelson et al., 2002). In 2002, nursing home residents received an average of 6.7 
routing prescription drugs daily, with an additional 2.7 as-needed medications. The 
number of medications prescribed in nursing homes increased by 14% in 2000.    
The aging of the Baby Boomer generation is predicted to increase the percentage 
of people over the age of 75, a cohort that was 5.8% of the population in 1997 and is 





more people to live longer (sometimes with less social support) and there are presently 
not enough nursing homes to care for the elderly population. According to NCCPPR 
(2013), the elder population in the state of North Carolina will double in 2030, increasing 
from 1.1 million to 2.2 million.  The Medicaid program will take up more portions of the 
state budget. Currently, the state Medicaid program provides healthcare services for 
people with low income, long-term care for the older population, and care for individuals 
with disabilities. As this growth continues, the state will need spend more on nursing-
home services because more people will qualify for Medicaid benefits. Is the state of 
North Carolina ready for this population growth, particularly with recent Medicare and 
Medicaid budget cuts? Or are there strategies the state can employ to improve the quality 
of healthcare services and decrease or at least control healthcare spending?   
Other components that affect the Medicare and Medicaid budgets include the cost 
for managing chronic diseases such as diabetes, cardiovascular disease, cancer, and 
asthma. For example, according to the CDC (2011), 23 million children and adults in the 
United States—about 8% of the population—suffer from diabetes. About 25% of the U.S 
population age 60 and older have diabetes, and it is estimated that by the year 2050, 48 
million U.S. residents will be diagnosed with diabetes (CDC, 20011). About 107 million 
people in the United States suffer from some form of chronic illness, and seven of 10 
people die from chronic disease every year. Heart disease, cancer, and stroke constitute 
the major share of these conditions, contributing to about 50% of all deaths each year 
(CDC, 2011). The cost of one chronic disease, diabetes, as reported by the ADA (2013), 





productivity amounting to $69 billion. The components that make up those diabetes 
medical expenditures include hospital in-patient care, which is 43% of total medical care; 
prescription drug to manage diabetes, which is 18%; and diabetic agents and other 
medical supplies, which account for 12%. Physician office visits are 9% and nursing 
homes/ residential facility stays are 8% (ADA, 2013). An increased understanding the 
economic consequences of diabetes and its determinants could help policy makers at both 
the state and federal levels to find ways to reduce healthcare spending. Heart disease, 
cancer, asthma, diabetes, and hypertension are among the five most costly chronic 
conditions in the United States. They cost the country about $347 billion in 2010, which 
is about 30% of total healthcare costs (CDC, 2011).  The number of individuals 
diagnosed with Alzheimer’s in the United States is increasing. It is reported that by 2050, 
the number of Alzheimer's cases will reach 16 million (CDC, 2011). This trend will 
impact Medicare spending; in fact, in 2005 Medicare paid $9 billion for individuals 
diagnosed with Alzheimer’s; by 2015, it was expected to reach $189 billion (CDC, 2011).  
The CDC (2011) reported that it costs the United States approximately $74 billion 
to care for a cancer patient (a treatment with Avastin costs more than $90,000 for a 1.5 
month period), and Medicare paid $7.3 billion on in-patient cancer care (CDC, 2011). 
Because chronic diseases account for much Medicare spending, any increase in the 
number of chronic conditions will impact the Medicare budget. Medications can help 
manage acute and chronic health conditions, and many older adults depend on several 
medications to help them manage health effectively. The current Medicare and Medicaid 





portion of their healthcare costs including prescription drugs. The remaining balance is 
considered out-of-pocket cost and is the responsibility of the recipient (CMS, 2012). The 
HSC (2003) revealed that many seniors in nursing homes are on low and/or fixed 
incomes and take more than one prescription drug to manage their chronic health 
conditions. Considering the high costs of prescription drugs, those with fixed and low 
incomes may find it difficult to pay for their Medicare and Medicaid out-of-pocket costs, 
including refilling their prescriptions (Strickland & Hanson, 1996). Medication is an 
essential aspect of managing chronic diseases, particularly for the elderly. Because social 
programs such as Medicare do not cover all aspects of prescription drugs, the elderly 
have difficulty affording drugs (Reed, Hargraves, & Cassil, 2003). 
Prescription drug costs are a burden for African Americans, as researchers have 
found that among African Americans age 65 and older, those using Medicare find it 
difficult to fill their prescriptions (Reed et al., 2003). The increase in chronic conditions, 
low income, and a lack of supplementary insurance explain the prescription access gap 
that exists between older African American and their European American counterparts 
(Reed et al., 2003). According to Reed et al. (2003), chronic conditions such as heart 
disease, high blood pressure, and diabetes are common among older African Americans, 
and they require prescription drug management. Additionally, complications that can 
result from diabetes such as renal failure, blindness, and gangrene because of lack of 
medication compliance can be avoided through proper prescription drug regimens (Reed 





According to Klein et al. (2004), the elderly sometimes delay refilling their 
prescripts due high costs. Not taking medication as prescribed can have health 
consequences; it could lead to further decline in health, result in repeated visits to the 
hospital, and may increase the number of days that the patient must stay in a nursing 
home. Beside the cost impact on individuals, prescription drug costs also impact other 
segments of society. In 2001, the cost of prescription drugs in United States was $141 
billion. Because seniors depend on Medicare prescription benefit programs to offset some 
of their prescription drug cost, containing drug costs could stabilize overall Medicare 
program costs (Haas et al., 2005). Generic prescription drugs are considered therapeutic, 
serve the same purposes as brand-name drugs, and are less expensive when compared to 
brand-name drugs. The United States Food and Drug Administration examines generic 
drug formulations and, if it finds them suitable, approves them as therapeutically 
equivalent to brand-name drugs in terms of safety, strength, and quality (Haas et al., 
2005). According to Haas et al. (2005), substituting generic drugs for the more expensive 
brand-name prescription drugs would provide savings for the drug-consuming 
population.  
Medicare and Medicaid are two social programs designed to provide medical 
support for many Americans, including the elderly. The demand for these programs will 
continue to increase because as the population grows, the increase in chronic conditions 
grows as well. As this trend continues, the nation and the individual states will continue 
to be challenged to find new ways to minimize costs while at the same time delivering 





incorporates automatic physician prescription of generic drugs will close the access 
prescription drug gap that exists between elderly American Blacks and their White 
counterparts, and it will further more create savings for nursing homes including those in 
North Carolina.   
In preparing this literature search, sources such as MEDLINE, CINAHH, Walden 
Library, Book, and CDC, ADA, FDA websites, including some nonpeer-reviewed 
articles were used to maximize search effectiveness while minimizing extraneous results. 
The following words were used in retrieving the relevant documents: Full text, HTML, 
Boolean methods, PROQUEST, EBSCO, and SAGE Full-Text.  
Articles that meet the following criteria were utilized for the literature review: (a) 
the study has bearing on the current research been undertaken, (b) full-text copy that 
includes a detailed description of the study including study design and methodology, and 
(c) the publication or article is written in English. The information obtained from the 
articles, books, and web sources are addressed and summarized in the following sections 
within Chapter 2 of the Literature review.  In the first two sections, chronic health 
conditions including diabetes and conditions that require treatment with medications are 
presented. Diabetes is included in the discussion because it is considered a chronic health 
condition, and many seniors who are residents of nursing homes including those in North 
Carolina suffer from diabetes.  In the third section, a historical perspective of the 
Medicare and Medicaid system is presented, and in the fourth section, the drug approval 
process, the costs of brand-name prescription drugs and generic drugs are presented. And 





affordability, costs to organizations and costs to individuals are presented. The sixth 
section includes a chapter summary. 
Theoretical Framework   
 The theoretical framework of this study will be based on the medical home model 
concept presented in 1967 by the American Academy of Pediatrics. The medical home 
model is characterized by the availability of a personal physician for every family/patient. 
The delivery of first-contact care is ensured by the physician in this model. 
Understanding of the needs of the family/patient and facilitation of co-management that 
is planned throughout the lifespan is also made certain by the physician. The physician 
must have the capacity and resources to fulfill the needs of the family/patient (Health 
Policy Brief, 2010).  
 The basis of this model rests on the delivery of patient-centered care that involves 
a team-based approach for facilitating a complete range of healthcare services. This 
includes the provision of care to all the age groups and at all stages including chronic 
care, acute care, mental and behavioral healthcare, end-of-life care, and preventive 
services. It also involves the coordination and integration of the care that is not delivered 
by the PCMH across entire fundamentals of the multifaceted healthcare system and 
patient community. The emphasis of this model is on the reduction of the cost of care by 
improving access to vigorous primary care. A promising way is represented by the 
medical home model for improving healthcare in America through the transformation of 
the process of organization and delivery of primary care (CAHPS, 2011). The medical 





medical home model.  Within this model, the primary care physician would be able to 
provide treatment while bearing the mind the affordability of the prescribed drug for the 
family/patient.  
   This theoretical framework has been selected because an approach is provided 
towards integrative healthcare by this model that is based on one main point of access. 
Most of the healthcare systems in the US are utilizing this model of healthcare for 
providing services to patients. An enormous amount of data can be retrieved through this 
model regarding the prescribing practices of primary care physicians in the state of North 
Carolina in Raleigh, and thus provide a better opportunity towards initiation of change in 
the practices of primary care physicians pertaining to their prescription practices. There 
are several studies that have utilized this model (Henderson et al.,  2012; Jaudes et al., 
2011). Lee et al. (2011) utilized this model to determine the possibility of elimination of 
disparities in healthcare that are encountered by the minorities in accessing the healthcare 
services. Windel et al. (2011) described the benefits of this model as it can be employed 
for shared decision making that can be useful for supporting the choices of patients in the 
prescription of drugs. Shared decision making permits the patients to be involved in 
selecting the most appropriate type of drug that is best for them from all aspects. This 
model can also help to curb the costs of healthcare through the utilization of medicines 
that are better preventatives and are more cost effective (Marshall et al, 2011). Therefore, 
this model has been utilized as a theoretical framework of this study because it can 





Cost of Chronic Conditions   
A chronic condition is a repeating health consequence that affects individual daily 
life, and it may last for several years (Anderson & Horvath, 2004). There is currently no 
cure for many chronic health conditions, but they can be managed adequately with 
medication. Chronic conditions are costly and tend to afflict the elderly population. It is 
estimated that more than 70 million Americans age 50 and older suffer from one type of 
chronic health condition, diabetes is one of them. According to the Robert Wood Johnson 
Foundation (1996), chronic conditions are a leading cause of death, and almost 100 
million Americans suffer from some form of chronic health issue. The projection is that 
by 2040 an estimated 160 million Americans will have a chronic condition of one sort or 
another. According to Anderson (2004), in 2002 in America 70% of all deaths in 2002 
were attributed to a chronic condition such as heart disease, 90% of seniors in America 
suffer from one form of chronic health condition, and 77% suffer from more than one 
chronic condition.  
Long-term care includes nursing home facilities. Nursing homes provide care to 
an increasing number of U.S. elderly persons who suffer from several chronic health 
condition including diabetes. A study conducted by Resnick, Heineman, Stone, and Shorr 
(2004) collected data on 11,939 from nursing home residents aged between 65 years 
representing 1.32 million individuals. In their study they found that in 2004, 24.6% of all 
nursing home admissions were suffering from diabetes at the time of admission. Also, 
those admitted with diabetic complications tended to be admitted from acute-care 





diabetic patients), and those admitted with diabetic complications typically had longer 
stays in the facility than non-diabetic patients. 
 A similar study conducted by Johnson, Brosseau, Soul, and Kolberg (2008) made 
the following observation about chronic diseases such as Type 2 diabetes: it affects 190 
million people globally, and it is reported that this number is expected to increase to 300 
million by 2025. Their study further revealed that patients residing in long-term care 
facilities often suffer from more than one chronic disease, with 25% suffering from 
diabetes, 80% suffering from cardiovascular disease, 56% suffering from hypertension, 
and a total of 69% of patients suffering from more than one chronic condition. The cost 
of managing chronic diseases has been a major concern for healthcare professionals 
because patients who suffer from multiple chronic diseases take more than one 
medication to manage their chronic conditions, and the high cost of prescription drugs is 
an issue. 
According to the American Diabetes Association (ADA, 2007), in 2007 there 
were 17.5 million people with diagnosed diabetes with an estimated cost of $174 billion 
in direct medical costs and indirect costs through lost productivity. A second study 
conducted by the ADA in 2013 that used a prevalence-based approach reported that the 
economic burden due to diabetes in the US in 2012 was $245 billion—a 41% increase 
compared to the previous study. The components that make up those diabetes medical 
expenditures include hospital in-patient care (43% of total medical care), prescription 





18%, antidiabetic agents and other medical supplies account for 12%. Physician office 
visits 9%, and finally nursing homes/ residential facility stays 8% (ADA, 2013). 
Murray and Callahan (2003) concluded in their study that American adults age 50 
and above suffer from multiple chronic diseases and require more than one medication to 
manage their chronic condition.  A research study conducted by DeVol and Beddroussian 
(2007) for the Milken Institute revealed that in 2003 treatment cost for seven chronic 
diseases totaled $277.7 billion. Treatment costs were highest for heart disease, at $64.7 
billion; for five leading cancer treatments, the combined cost was at $48.1 billion; mental 
health disorders reached a total treatment cost of $45.00 billion; pulmonary conditions 
cost $45.2 billion; hypertension came in at $32.5 billion; diabetes was at $27.1 billion, 
and stroke accounted for $13.6 billion. 
Klonoff (2008) reported that the cost of prescription drugs is on the rise, 
particularly for diabetes medications. His study revealed that as of 2007, treatment of 
diabetes become the leading source of increased spending on prescription drugs.  The 
CDC (2009) revealed that approximately $7,900 was spent in 2009 to manage chronic 
conditions, this will translate into $3 out of every $4 spent on the nation’s healthcare. The 
agency further revealed that it cost $432 billion per year to treat heart disease and stroke, 
while lung disease cost $ 154 billion per year, and Alzheimer’s disease cost $148 billion 
per year. The long-term effects of chronic diseases add to suffering and chronic pain, and 
unfortunately many Americans in this situation continue to face rising healthcare costs 
while in many cases access to care is limited. The financial burden on individual, families 





There are several components that contribute to healthcare cost. These include the 
high cost of prescription drugs and the cost it takes to manage chronic diseases such as 
diabetes. The Robert Wood Johnson Foundation (1996) found that the cost of caring for 
Americans with chronic conditions was $470 billion in 1995, and by the year 2040 that 
cost is estimated to reach $864 billion.  
The share of Medicare beneficiaries with more than one chronic condition 
increased from 30% in 1987 to 50% in 2002 (Thorpe & Howard, 2006). Chronic 
condition management varies by treatment, its cost is a burden to society, and it affects 
public programs such as Medicare and Medicaid. Holahan, Schoen, and McMorrow 
(2011) reported that it cost the U.S. public health programs about $635 billion in 2010 to 
manage chronic illness: This is about 30% of total U.S. healthcare spending, and nearly 
half of that $635 billion–an estimated $304. 5 billion–was spent on beneficiaries of 
Medicare and Medicaid.   
The ADA’s 2007 report also revealed that a total of 168 million inpatient hospital 
days in the U.S was attributed to one chronic condition alone, diabetes and an estimated 
one-third of all nursing days stay was attributed to diabetes. Increased understanding of 
the economic consequences of diabetes and its major determinants will help policy 
makers at both the federal and state levels to formulate polices that will address the 
prevalence of diabetes and its associated economic burden. Since most hospitals, nursing 
homes, and the elderly depend on Medicare and Medicaid program payments and 
benefits, current reductions in Medicare and Medicaid payments mean that proper 





Heart disease, cancer, asthma, diabetes, and hypertension are among the five 
leading most costly chronic conditions in the US. Together, these cost the country about 
$347 billion in 2010, or about 30% of total healthcare spending (CDC, 2011).  The 
number of individuals diagnosed with Alzheimer’s in the US is increasing, and it is 
predicted that by 2050 the number of Alzheimer’s cases will reach 16 million (CDC, 
2011). This trend will greatly impact Medicare spending. In fact, in 2005 Medicare paid 
$9 billion for care of individuals diagnosed with Alzheimer’s; by 2015 it will reach $189 
billion (CMS, 2005).  
Chronic Condition Treatments   
Prescription drug cost is a major concern to so many Americans and it plays a 
major role in managing ill health. According to Reed et al. (2003), chronic conditions 
such as heart disease, high blood pressure, and diabetes that are very common among 
older Black Americans can be managed effectively with prescription drugs.  
Additionally, complications that can result from diabetes such as renal failure, blindness, 
and gangrene can be avoided by following a proper prescription drug regimen (Reed et 
al., 2003).       
Besides prescription drug costs, there are other components that impact healthcare 
costs. These include chronic conditions such as cardiovascular diseases, cancer, and 
diabetes. State government also feels the cost of ill health as a result of chronic 
conditions, and without some form of an aggressive intervention these rising cost trends 
will continue. The issue of pharmaceuticals can play a major role.  According to the 





diabetes continues to rise, it disproportionally affects the elderly, and it is higher among 
racial and ethnic minorities. Type 2 diabetes can be managed effectively with diet and 
oral diabetes medications. Data from a randomized controlled trial demonstrated that the 
risk of retinopathy can be reduced by improving glycemic control in individuals suffering 
from Type 2 diabetes (ahrg, 2005).  
The two types of drugs use in treating Type 2 diabetes in 1995 were sulfonylurea 
and insulin. However, there are many more new pharmacotherapy options available 
today. Currently in the US there are 11 classes of diabetes prescription drugs, including 
biguanides (i.e., metformin), thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 
(DPP-4) inhibitors, meglitinides, glucagon-like peptide-1 (GLP-1) receptor agonists, 
amylin analogue, bromocriptine, alpha-glucosidase inhibitors, colesevalam (a bile-acid 
sequestrant), and insulin (ahrg, 2005). All of these drugs work differently, and it was 
reported that between 1999-2000, about 6% of Type 2 diabetic patients were taking only 
three classes of medication, as compared to 2005 - 2006 when 35% of such patients take 
two classes of antidiabetes medication and 14% take three or more classes (Ahrg, 2005). 
American adults within the age of 50 years and above suffer from multiple 
chronic health conditions and require more than one medication to manage their chronic 
health condition (Murray & Callahan 2003). According to Murray and Callahan (2003), 
the use of medications including diabetes medications has several benefits: it improves 
quality of life, preserves cognition and physical functioning, reduces economic burden on 





Better management of diabetes that includes the use of diabetic agents is critical 
in reducing the economic burden presented by this disease; however, the cost of 
prescription drugs in its treatment is an issue. According to Klonoff (2008), in 2007 
diabetes medication accounted for 7% of prescription drug spending. Medco in 2007 
reported that diabetes medication is number one as a top therapeutic category 
contributing to increased drug spending in the US (Klonoff, 2008). Future diabetes drug 
cost trend will be affected by new approved drugs, and the predicted prevalence increase 
in diabetes will increase drug utilization and thus drug costs. Generic prescription drugs 
are effective in the management of chronic diseases including diabetes because they have 
almost the same components as the brand-name prescription drug and cost less (Klonoff, 
2008). 
Heart disease can cause death in men and women. Hypertension, high levels of 
cholesterol, obesity, and diabetes are known to be complications associated with heart 
disease. A daily dose of aspirin can prevent heart disease, and statin medications are 
known to lower cholesterol levels. Hypertension can be managed with a combination of 
drugs; they include angiotensin converting enzyme (ACE) inhibitors, water pills or 
diuretics, beta-blockers, and calcium channel blockers.  
There are two class of chemotherapy drug for treating cancer; they include 
alkylating agents and antimetabolites. Chemotherapy drugs such as alkylating agents 
work by damaging the DNA of the target cells and thus preventing reproduction; they are 
used to treat leukemia, lymphoma, Hodgkin’s disease, cancer of the breast, and lung 





RNA growth by the process of substitution. They are used to treat leukemia, cancer of the 
breast and ovarian cancer. 
Historical Perspective of Medicare and Medicaid   
The Social Security Act of 1965, commonly referred to as Title XVIII, was 
implemented to provide health insurance benefits for the aged and the disabled persons. 
The Act was later amended in 1966 to provide coverage for persons age 65 and older 
through the Medicare payment system (Stephen & Torrens, 2002). Medicare is a 
federally sponsored program, while Medicaid is a partnership program between the 
Federal government and the states. Both programs provide meaningful support for and 
play a crucial role in the U.S. health delivery system. Hospitals and nursing-home 
residents who need special services with chronic health conditions depend on Medicare 
and Medicaid for insurance benefits. With increases in the U.S. elderly population as a 
result of the baby boomer generation, increases in chronic health conditions and recent 
reductions in both programs, those that depend on these programs may have to come-up 
with additional out-of-pocket fees to cover for needed medical services. 
Medicaid     
After much debate from Congress, the legislation to establish Medicare and 
Medicaid program under Title XVIII and Title XIX was enacted into law in 1965 
(Stephen & Torrens, 2002). Medicaid was established as a public response to the lack of 
medical care available under public assistance. Both programs were originally managed 





programs were transferred to the Center for Medicare and Medicaid Services (Stephen & 
Torrens, 2002).   
Title XIX was established as the Medical Assistance program and it was later 
known as the Medicaid program which was expanded through the Kerr-Mills Medical 
Assistance program for the aged (Stephen & Torrens, 2002). Funding for Medicaid is 
supported by the federal government and administered by the states, eligibility for 
Medicaid is limited to low-income individuals and families. Title XIX of the Medicaid 
program mandates the states to provide the following basic health related services: 
hospital in-patient care, hospital outpatient services, nursing home care for those age 21 
and older, diagnosis, laboratory, and X-ray services. Additional services under the 
program include a prescription drug benefit, and physician services. 
Healthcare spending in the U.S. saw significant growth over last few decades. For 
example, in 1960 it was $27.5 billion, and in 1993 it was $912.6 billion with an average 
increases of 11.2% yearly (CMS, 2007). While healthcare spending saw a decline of a 
relatively small amount in the years 1993 to 1999, it picked up in the years between 1999 
and 2002, rising 7.0% in 2000, 8.6% in 2001, and 9.1% in 2002. As a share of gross 
domestic product (GDP), healthcare spending in the US rose from 13.8% of GPD in 2000 
to 16.0% in the year 2005. For the number of 297 million residing in the U.S, average 
healthcare expenditure in the year 2005 was $6,697 per individual (CMS, 2007). 
The largest share of healthcare spending for the US under the CMS comes from 
Medicare, Medicaid, and the State Children’s Health Insurance Program (SCHIP). 





2007).  Since the implementation of Medicare and Medicaid programs, there have been 
many legislative initiatives and public outcries to make changes that will help the 
nation’s aged, disabled, and disadvantaged. 
Medicare   
Title XVIII was known as the Social Security Act of 1965, and it was designed as 
a health insurance program to help the aged and the disabled. This program is now called 
Medicare (Stephen & Torrens, 2002). First implemented in 1966, Medicare provides 
coverage for individuals age 65 and older, and in 1973 railroad retirees and individuals 
with end-stage renal diseases (ESRD) became eligible.  
Medicare when it was first designed contained two components: A part known as 
the Hospital Insurance (H1), or part A; and the other part is called the Supplementary 
Medical Insurance (SMI), or part B. Part A provides for in-patient hospitalization, home 
health, skilled nursing facility care, and hospice care. Part B, the Supplementary Medical 
Insurance component, covers physician services, home health care, outpatient 
hospitalization, and other services. Part B eligible patients pay a premium (Stephen & 
Torrens, 2002).  There is a third component to the Medicare program—Part C, the 
Medicare Advantage program. This program was established under the Medicare 
+Choice program by the Balanced Act of 1997. This program later become the Medicare 
Prescription Drug, improvement, and Modernization Act (MMA) that was enacted into 
law during the Bush Administration.  
Since 2006, the MMA program provides prescription drug insurance coverage at a 





private health insurance plans. Since July 1, 1996, those enrolled in the Medicare 
program total 19 million that number grow to over 44 million in 2007 for both Part A and 
Part B Medicare programs, and about 8 million for the Medicare Advantage plan. In the 
year 2006, Part A Medicare program provided hospital care for about 43 million persons, 
36 million aged and 7 million disabled persons, and total Part A benefit cost was $189.0 
(CMS, 2007). Medicare Part A provides the following services: in-patient hospitalization, 
coverage under this part includes cost of semi-private rooms, meals, regular nursing 
services, operating room services, prescription drugs, laboratory tests, psychiatric 
consultations, long-term care when it is medically needed, in-patient rehabilitation, and 
X-ray services. Deductibles and copayments are required under the Part A Medicare 
program. Additional services under part A include skilled nursing facility services. Under 
this part, care is given only if it is within 30 days of a hospitalization and required for 3 
days or more. Coverage is the same as defined under in-patient hospitalization, the 
number of days under this part is limited to 21-100 days, and copayment is required. Part 
A does not pay for skilled nursing services if patients do not fall under skilled services 
and skilled rehabilitation. Hospice and home health agency are covered under Part A 
Medicare. Part B Medicare Services provides some limited services and supplies, 
including diagnosis, laboratory and X-ray services ,home healthcare not covered by Part 
A, preventive and screening services, physical and occupational services, speech 
pathology services, radiation therapy, dialysis services, and transplant services. Also 





Part A and Part B Medicare programs, the new Part D Medicare program provides a 
prescription insurance benefit for most FDA-approved prescription drugs.  
Medicare is Different from Medicaid    
Medicare and Medicaid are both under federal funding. Medicare is an insurance 
program that is sponsored in part by the federal government and through premiums paid 
by those who are enrolled in the program. The Medicare program is run by the 
Department of Health and Human Services through contracted fiscal intermediaries 
called the Center for Medicare and Medicaid Services (CMS, 2012). Because Medicare is 
a national program, coverage from state to state does not vary. Also, as an entitlement 
program, every American that meets the age and disability requirements qualifies. 
Medicaid on the other hand is designed as a means–tested program: certain criteria must 
be met before eligibility, such as household income, resources, and asset level (CMS, 
2012).  
Medicaid is a joint partnership between the federal government and the states, 
with 57% of program funding coming from the federal government, and 43% from the 
states. Because Medicaid is an entitlement program, states cannot limit the number of 
persons who are covered so long as those individuals meet established guidelines for 
coverage. According to CMS (2012), North Carolina has about 1.8 million individuals 
enrolled in the Medicaid program. This represents 19.5% of the total North Carolina 
population. Reports from the state of North Carolina revealed it cost the state about 
$6,424 for each single enrollee. With increased enrollment in the future for 766,200 





benefits may prevent these two key public programs from meeting their obligations, so 
some cost containment strategies is necessary for the state of North Carolina. 
Nursing homes play an important role in the delivery of healthcare services, 
particularly to the elderly who lack the ability to care for themselves. Most of this 
vulnerable population is on a low fixed income, suffers from multiple chronic conditions, 
and depends on Medicare and Medicaid to help pay for health services including 
prescription drugs. However, the cuts imposed by CMS in 2011 will significantly impede 
nursing home facilities from delivering quality care. Medicaid covers nursing home 
services, and Medicare through Part D provides for prescription drug benefits, but the 
reduction enacted by CMS will exacerbate existing Medicaid shortfalls. Medicare 
payments are important because they help nursing homes to cover cost of care for 
Medicaid-funded patients, thus helping nursing homes to remain viable. With the 
increases in chronic conditions for the elderly and the aging of in the baby boomer 
generation, the need for nursing homes will increase. Unless policy makers look for ways 
to address current Medicare and Medicaid cost-reduction issues, there will not be enough 
nursing home facilities available to accommodate the baby boomer generation. 
Drug Approval Process   
The Food and Drug Administration (FDA) is an agency within the U.S. 
government that regulates the nation’s food and drug supply. In 1938, Congress passed 
the Food, Drug, and Cosmetic Act as a result of 107 deaths from Elixir Sulfanilamide, a 





was passed in 1938 gave the FDA the authority to require evidence of drug and food 
safety before allowing them to be sold to the consuming public.  
It is worth recapping a brief timeline concerning the history of the generic drug 
approval process. In 1968, a Drug Efficacy Conference was convened through the 
National Academy of Science/National Research Council to oversee all drugs approved 
between 1938 and 1962 for drug safety. The agency gave drug companies a 2-year grace 
period to provide supportive evidence of drug effectiveness (Peters et al., 2009). In 1984, 
the Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act) was 
passed by Congress. The act allowed the FDA to approve the manufacture of generic 
drugs without requiring repetition of the research conducted by the original innovator to 
prove drug safety and efficacy. The same act also allows for patent extensions and 
exclusivities to innovators’ drug firms.  
The goal of the Hatch-Waxman Act was to introduce generic medication that is 
equivalent to brand-name drugs, but costs far less when compared to brand-name drugs. 
Before being approved, new drugs must meet certain standards set forth by the FDA The 
manufacturer must provide evidence after a rigorous process that the drug is safe and 
effective, and after the patents expire, other companies interested in manufacturing the 
generic form of the original drug can do so under the guidance of  the FDA (Peters et al., 
2009).  For a generic medication to be considered a substitute for a brand-name drug, the 
FDA requires that certain applicable guidelines be meet, including that the generic drug 
must have the same clinical effect and safety profile when given to patients under the 





the brand-name drug, it must be pharmaceutically equivalent and bioequivalent, and it 
must be produced in accordance with current manufacturing best-practice regulations. 
Brand-name versus generic drug. A brand-name drug by definition is a 
medication or medicine that is researched, developed, and marketed by a pharmaceutical 
company and sold under an exclusive patent-protected brand name. When the new 
medication is discovered, the company that first discovered the drug files for a patent. 
This process prevents other drug manufacturers from copying and selling the new drug 
(FDA, 2013). A drug has two names: the generic drug name is the common scientific 
name; the other name is the brand name of the drug. This name makes the drug stand out 
in the marketplace. This is true for both prescription medications and over-counter 
medications. A commonplace example of this is the pain killer sold under the brand name 
of Tylenol: the generic name is acetaminophen.  
The FDA approves the manufacture and distribution of a generic drug because it 
has the same active ingredients as its brand-name drug counterpart. Usually generic 
medication is available to the public when the patent expires (patents normally last for 20 
years for most drugs). When the patent expires, the original drug developer may decide to 
make the generic form of the original medicine, or other drug manufacturers may decide 
to make the generic version of the original drug (FDA, 2013).  
Generic medication has some similarities and differences when compared to 
brand-name medications. The FDA requires that to substitute generic drug for brand 
name drug, the generic version must contain the same active ingredients contained in the 





dosage form (e.g., liquid or pill form), and finally the generic drug must deliver the same 
amount of drug to the bloodstream within the same time period (FDA, 2013). Federal law 
requires that generic drugs have different sizes, shapes, and color markings, may have 
different inactive ingredients. Generic medications are developed and manufactured by 
different drug manufacturing industries and cost far less when compared to brand-name 
drugs. It has been reported that generic drugs can cost between 20- and 80% less when 
compared to their brand-name counterparts (FDA, 2013). 
  Cost difference between brand-name and generic drug. It takes several years 
before new medications reach the consuming public. Research, clinical studies, 
advertising, and manufacture of a new medication is costly. Generic versions of the same 
drug do not have the development and research cost, and as a result generic medication 
cost less than brand-name medications (CBO, 2010). The issue of not prescribing generic 
medication automatically has been a concern for many, particularly with so much cost 
difference. Generic medications are barred under patent provisions for up to 20 years for 
most drugs (FDA, 2013). 
  Considering brand-name versus generic drugs is critical in managing the critically 
or chronic ill patient because the cost of prescription drugs is high, Medicare and 
Medicaid are having difficulty meeting their obligations because of skyrocketing 
healthcare costs, and many in society cannot afford prescription drugs. Educating the 
public as to the benefits of generic drugs and encouraging prescribing physicians to 





  Prescription drug cost. The cost of prescription drugs has been a major concern 
for many, but especially so for the elderly, healthcare organizations, and policy makers. 
For example, the overall cost of prescription drugs in the US reached $307 billion in 
2010, according to the CBO, an increase of $135 billion since the year 2001. This 
expenditure comprised about 12% of all healthcare spending in the US. The rise in the 
cost of diabetes medication, the increase in chronic health conditions, the delays in 
issuing generic drugs due to patent laws, and the costs of brand-name medications are 
among some of the drivers of prescription drug cost.  
Generic medication is available to the drug consuming public at the expiration of 
the original patent covering a brand-name drug. Yet, doctors do not prescribe generic 
drugs as often as they do brand-name medications. This may be because of lack of 
knowledge bout generics, insufficient time to research the availability of newer generic 
drugs and what costs less, and the fact that physicians have different drug experiences 
and belief systems concerning drug efficacy. Medical insurance dictates and personnel 
preferences also play key roles. 
A generic drug is a pharmaceutical product intended to be interchangeable with a 
brand-name product that is manufactured without a license from the drug’s originating 
company and marketed after the expiry date of the drug’s patent or other exclusive rights. 
Generic drugs are marketed under a non-proprietary or approved name rather than a 
proprietary brand name. Generic drugs are usually as effective as, but much cheaper than, 
brand-name drugs. For example, paracetamol is a chemical ingredient found in brand-





drugs are often the only prescription drug that the non-wealthy can access. The Trade-
Related Aspects of Intellectual Property Rights (TRIPS) agreement does not prevent 
governments from requiring accurate labeling or allowing generic substitution. It is 
argued that competition between drug companies and generic producers has been more 
effective than negotiations with drug companies in reducing the cost of drugs. The price 
of the average generic drug is 75% cheaper than the retail price of the equivalent brand-
name prescription drug (CBO, 2010).  
The cost of prescription drugs totaled $100 billion in 1999, and it is considered 
the fastest growing part of personal health expenditure, the most affected is the 13 million 
US population that are under Medicare benefit who do not have insurance medication 
after hospitalization (Korn et al., 2003). The elderly have also seen cost of prescription 
drug jump, going from $28.50 in 1992 to $42.30 in 2000 and is still increasing as a result 
of the cost of prescription drugs and the number of prescriptions being written (Korn et 
al., 2003). Haas et al. (2005) reported that in 2001 the national expenditure for 
prescription drugs was $141 billion. Another study conducted by Holahan and Cohen 
(2006) revealed that spending on prescription drugs is among the fastest growing public 
programs in recent years, and recent trends have seen an average growth of 16% in 
Medicaid spending between 2000 and 2004. This growth put state Medicaid program 
prescription cost at $30 billion per year. Holahan and Cohen’s 2006 study also found that 






Prescription drug costs impact every segment of society. For example Gellad, 
Huskamp, Phillips, and Haas (2012) reported that the out-of-pocket cost of prescription 
drugs is a serious concern for racial and ethnic minorities, as well as for the near poor, 
including seniors with chronic conditions. On January 1, 2006, the Medicare Prescription 
drug benefit (Part D) became law. The intention of the program was to expand drug 
benefit coverage for the elderly population, including those in nursing homes with 
chronic conditions.  
Reports from the National Health Expenditure Accounts (NHEA) revealed that 
healthcare spending reached $2.6 trillion in 2010. This is about $8,402 per person, and 
represents about 18% of the U.S. GDP, (CMS, 2012).The U.S. government financed 29% 
of healthcare costs in 2010, (an increase from 23% in 2007), and state and local 
government paid another 16%.  Further analysis from NHEA report indicates that 
average yearly healthcare cost is expected to grow by 6.2% through 2018, a number that 
surpasses the anticipated overall economic growth of 4.1 for the same period, and by 
2018 it is reported that national healthcare spending will reach $4.4 trillion (CMS, 2012). 
At this growth rate, in 15 years healthcare cost will amount to 50% of U.S. GDP. The 
question becomes whether or not the U.S. economy is sustainable with this level of 
expenditure.  
Prescription drugs are often dispensed in hospitals and long-term care facilities 
for the management of chronic diseases. It is reported that the price of the average 
generic drug is 75% less than the retail price an equivalent brand-name prescription drug 





There are several drivers that contribute to the nation healthcare cost, the driver’s 
includes chronic health condition such as diabetes, the growing elderly population, and 
prescription drug cost. It is reported that prescription drug spending in the U.S reached 
$307 billion in 2010, this is an increased from $135 billion in 2001, this figure comprises 
of all healthcare spending of 12% (IMS Health, 2011). In the early 2000s, cost of drug 
was among the fastest growing driver of healthcare spending but this spending declined 
as a result of greater generic medication availability and the expiration of patents. 
Generic drug is therapeutic and serve the same purpose as brand name drug and cost less 
when compared to brand name drug (CBO, 2010).  
Several studies conducted on generic prescription drugs have shown conclusively 
that the use of cheaper generics are a critical part of what will hold down the growth of 
healthcare cost both nationally and across institutional settings such as hospitals and 
long-term care facilities. Studies also show that the use of generic drugs saved the U.S. 
healthcare system about $1.07 trillion from 2002 through 2011, with $192.8 billion in 
savings in 2011 alone (CMS, 2012). Knowing that the U.S. government share of 
healthcare spending will soon reach 30%, and as the oldest baby boomers become 
eligible for government-sponsored program such as Medicare, increased use of generic 
prescription drugs is critical in bending the curve of Medicare and Medicaid 
sustainability.  
This literature review identified cost-saving approaches from various studies. 
Some researchers looked at estimates that result because of the use of generic drug, 





therapeutic substitutions. Additionally, other studies examined savings for the U.S. 
healthcare system, and savings from program implementations (CBO, 2010; Haas et al., 
2005; Scott & O’Donnell, 2007). 
Multiple studies conducted for the Generic Pharmaceutical Association (GPhA) 
showed analytic estimates of the amount spent on generic drugs and brand-name drugs 
for the years 1999 through 2010. The report found that generic substitution saved the 
U.S. healthcare system about $1 trillion during that period, and that in 2010 alone generic 
substitution saved the U.S. healthcare system more than $157 billion (GphA, 2011). The 
Congressional Budget Office (CBO) in 2010 examined savings that resulted because of 
the use of generic drugs in the Medicare Part D prescription drug program. Based on 
claims data, the CBO found that substituting generic drugs for brand-name drugs resulted 
in a cost saving of $33 billion in 2007 (CBO, 2010).  
The CBO study further evaluated the additional savings from generic and 
therapeutic substitution, and found that an increase in generic substitution rate of 100% 
would have resulted in cost savings $900 billion for generic use and additional cost 
savings of $4 billion for therapeutic substitutions in 2007 (CBO, 2010). Another study 
analyzed cost savings through program implementation in a managed-care organization 
in the form of physician participation in 2005 and 2006 of those that did not participate, 
the study found that after program cost the organization saved $397, 486 in 2005 and 
$453,545 in 2006 (Scott & O’Donnel, 2007). Yet another study used Department of 
Veterans Affairs (VA) data to examine policy implementation in a VA hospital to 





found that from March of 2002 through August, the policy resulted in a savings of $2.5 
billion (Dobscha et al., 2007).  
Two particular studies used claims data from 45 private health insurance 
organization plans from 2003 through 2007 to compare the cost of health care in 
individuals using SSRIs when mid-treatment occur in therapeutic substitution. The study 
found that patients who switched from brand-name drugs to generic drugs had higher 
hospitalization because of switching from brand name drug to generic drug in 
midtreatment, the switched also result in generic use of healthcare cost of $881 dollars 
(Wu et al., 2011). A similar study conducted by Viahiotis et al.  (2011) reached a 
different conclusion: their study used claim data from 2005 to 2007and compared the 
healthcare costs of using brand-name drug versus generic drugs in mid-treatment for 6 
months. Their conclusion was that the cost of generic antidepressant SSRIs was 
significantly lower when compared to brand-name medications—the average costs were 
$3,660 and $4,587 respectively.             
The projected cost of the Medicare Part D prescription drug program is estimated 
to reach $700 billion for 2006 through 2015. Despite the promise of extended coverage, 
the very nature of the program may require additional out-of-pocket payments from those 
that the program is supposed to help, particularly with respect to the gap in coverage 
known as “the doughnut hole” (Gellad et al., 2012). Gellad et al. (2012) examined data 
from 1996 through 2000 from the Medical Expenditure Panel Survey Household 
Component (MEPS-HC), and concluded that the prescription drug Part D program as 





poor, including seniors with chronic conditions. The rise of prescription drug costs is a 
central policy issue for both Medicare and Medicaid programs. The incidence of chronic 
health conditions is on the rise, the elderly population is growing, and prescription drug 
costs are also high. According to the U.S. Census Bureau (2002), the baby boomer 
generation age over 75 populations will increase from 5.8% in 1997 to 9.4% in 2025. It is 
also reported by the same agency that because of advances in medical science, those with 
chronic conditions are living longer; however, there will be a lack of social support 
including adequate appropriate housing. Thus, increasing the number of nursing home 
facilities is critical. 
Currently, many states are concerned about the increase in prescription drug costs 
in nursing homes because of aggressive cuts to state Medicaid programs. Second, newer 
drugs have been developed to help the management of many chronic conditions, but these 
newer drugs are expensive. Finally, nurses and other health professionals are concerned 
about the increased use of pharmaceuticals in nursing homes. According to Mendelson et 
al. (2002), an individual in a nursing homes receives an average of 6.7 routine 
medications per day, with an additional 2.7 as needed medication per day. Nursing homes 
are financed by three payment systems: Medicare, Medicaid, and private sources (this 
includes personal funds and long-term care insurance). 
Recent cuts in two major social programs will impact the way nursing homes are 
financed. For example, the prescription drug benefit under Medicare Part D is designed to 
help with the costs, but the structural design of the program can require additional out-of- 





Tripoli (2010) in their retrospective study of Medicare Part D of 12,881 diabetes patients 
age 65 concluded that the coverage gap—the so-called “donut hole” in Medicare Part 
D—had a negative impact on diabetes medication adherence. A similar study conducted 
by Piette et al. (2004) concerning out-of-pocket costs of diabetes reported that out-of-
pocket cost is a significant burden to many older adults with diabetes. Their study further 
revealed that diabetes patients in that study under-use their medication because of out-of-
pocket cost. Several studies revealed that lack of medication compliance may lead to 
further declines in health, poor quality of care, and for diabetes patient glycemic control 
is almost impossible without adherence to their drug regimen. 
One of the contributing factors of healthcare cost is medication noncompliance. 
Piette et al. (2004) reported that older adults who suffer from diabetes do not adhere to 
their medication regimen due to out-of-pocket cost, and lack of medication adherence 
may lead to noncompliance. A study conducted by Mahoney, Ansell, Fleming, and 
Butterworth (2008) concluded that medication noncompliance results in 125,000 annual 
deaths, and accounts for 10- to 25% of all hospital and nursing home admissions. Klein et 
al. (2004) conducted a cross-sectional study of a national sample of 6,535 elderly people, 
and concluded that the elderly delay refilling their prescription drugs as a result of high 
prescription drug cost. Felland and Reschovsky (2009) found that drug affordability 
continued to be a major concern, not only within the adult U.S. population but also 
among children, and some working-class Americans cannot afford their prescription 
drugs due to cost. That study also found that in 2007, one in seven Americans under the 





10). Their study also revealed that the most vulnerable are those with low incomes, the 
uninsured, and the individuals suffering from chronic conditions. 
  Generic drugs are not different from brand-name drug. The cost of 
prescription drugs has been a major concern for many, including the elderly, healthcare 
organizations, and policy makers. For example, the total cost of prescription drugs in the 
U.S. reached $307 billion in 2010, according to the CBO, an increase of $135 billion 
since the year 2001. It has been reported that generic medications are equivalent to brand-
name drugs in terms of efficacy, and generic drugs cost far less. Generic medication 
usually becomes available to the public upon the expiration of the brand-name drug’s 
patent (FDA, 2013). In 1984 the Hatch-Waxman Act (Drug Price Competition and Patent 
Term Restoration Act) was passed by Congress. The Act allows the FDA to approve the 
manufacture of a generic drug without requiring repetition of the research conducted by 
the original drug innovator to prove drug safety and efficacy. The same act also allows 
for patent extensions and exclusivities to innovator drug firms. The goal of the Hatch-
Waxman Act was to introduce generic medication that is equivalent to brand-name drugs 
but costs far less when compared to the brand-name drug.  
The bioequivalence of generic drugs to brand-name drugs has been documented 
in several articles. For example, a study conducted by Peters et al. (2009) revealed that 
generic drugs are safe, effective, and affordable when compared to brand-name drugs. 
Another study conducted by Kesselheim et al. (2010) consisted of a systematic review 
and meta-analysis of seizure outcomes following the use of generic versus brand-name 





brand-name drugs. Kesselheim et al. (2008) conducted a meta analysis to compare 
generic and brand-name medications for patients suffering from cardiovascular disease. 
This study concludes that the brand-name drug was not superior to the generic 
medication in treating cardiovascular disease. The FDA requires that a generic drug be a 
copy of a brand-name drug because it has the same dosage, safety, and strength, quality, 
and performance. The FDA also requires that the only allowable differences between 
generic drugs and their brand-name counterparts are shape, scoring, release method, 
packaging, colors, flavors, and preservatives (FDA, 2013).    
  Generic drugs and cost savings. The Restoration Act of 1984 was enacted to 
regulate generic drugs, and the addition of the Hatch-Waxman Act was to strike a balance 
between drug innovation and cost-saving generic drug development through proper drug 
approval process. The FDA requires that for a generic drug to be pharmaceutically 
equivalent to a brand -name drug, it must have the same active ingredient. Several studies 
have revealed that generic medication is identical to the brand-name drug counterpart 
(Kesselheim et al., 2010; Peters et al., 2009).  
The prevalence of chronic conditions such as diabetes is on the rise, and so is the 
cost of prescription drugs. For example, the cost of prescription drugs totaled $100 billion 
in 1999, and it is considered the fastest growing part of personal health expenditures. 
Those most affected include the 13 million Americans who are receive Medicare benefits 
who do not have insurance medication after hospitalization (Korn et al., 2003). 
According to the American Diabetes Association (ADA, 2007), in 2007 there were 17.5 





expenses and lost productivity. A similar study conducted by the ADA in 2013 that used 
a prevalence-based approach reported that the economic burden for diagnosed diabetes in 
the US in 2012 was $245 billion. This is a 41% increase compared to their previous 
study. Proper glycemic control is critical in the management of Type 2 diabetes. 
Currently there are several medications on the market to accomplish this objective; 
however, prescription drug prices continue to increase. Diabetes is common in nursing 
home facilities and among the elderly population, but recent cuts in Medicare and 
Medicaid benefits mean that some elderly patients have not been able to afford their 
prescription drug because of cost. This may negatively impact effective diabetes 
management.      
The use of generic drugs as a cost-saving alternative to brand-name drugs has 
been supported by several research articles. Shank, Choudhry, Liberman, and Brennan 
(2011) conducted a study to compare the importance of controlling blood pressure in 
non-diabetic patients. Their study concluded that previous studies found that the use of 
brand-name drugs cost an estimated $52,983 per quality-adjusted year life, but their study 
found that by using generic drug the cost was $7,753 per quality-adjusted year life. 
According to Haas et al. (2005), substituting generic drugs for the more expensive brand-
name prescription drug will provide savings for the drug consuming population. Peters et 
al. (2009) revealed that generic drug is safe, effective, and affordable when compared to 
brand-name drugs. Fischer and Avorn (2003) conducted a study to analyze state-by-state 
Medicaid prescription drug spending in 2000. They concluded that in 2000, Medicaid 





name and generic medications. Their study further revealed that they identified a 
potential savings of $229 million from the use of generic prescription drug. 
A report from the Congressional Budget Office revealed that in 2007 total 
expenditures for the Medicare Part D prescription drug benefit was $1 billion, and total 
payment for pharmacies and other plans was $60 billion. Using Part D prescription drug 
data, the Congressional Budget Office (CBO, 2010) reported that dispensing generic 
drugs rather than brand-name reduced prescription drug cost by $33 billion in 2007, and 
that total payment to plans and pharmacies would have been $95 billion without generic 
substitution. 
Summary   
The literature reviewed thus far revealed several relevant issues. For instance, the 
literature revealed that there are several drivers that increase healthcare cost, these drivers 
include the high cost of brand-name prescription drugs, the prevalence of diabetes and 
other chronic health conditions, and an increasing older population as a result of the 
aging of the baby boomer generation. For example, according to the American Diabetes 
Association (ADA, 2007) in 2007 there were 17.5 million people with diagnosed diabetes 
with an estimated price tag of $174 billion in medical costs and lost productivity. The 
prevalence of chronic conditions such as diabetes is on the rise, and so is the cost of 
prescription drugs. For example, the cost of prescription drugs total $100 billion in 1999, 
and it is considered the fastest growing part of personal health expenditure. The 
population most affected is the 13 million Americans who receive Medicare benefits but 





cost of prescription drugs in the US reached $307 billion in 2010, according to a CBO 
report—an increase of $135 billion since the year 2001. 
The cost of prescription drugs to the Medicaid program is $30 billion per year, 
and in 1990 Medicaid expenditures were 7%, but has climbed over 14% in recent years. 
With this amount of healthcare cost, Medicare and Medicaid will have trouble meeting 
their obligations to the state nursing home healthcare delivery system. If the cost of 
prescription drugs is among the contributing factors to rising healthcare cost that is 
impacting public programs such as Medicare and Medicaid, and generic drugs are 
therapeutically equivalent to brand-name drugs, why are physicians not automatically 
prescribing generic drugs?  Chapter 3 of this study will focus on methodology, and the 
following areas will be discussed: research design, justification for the design, ethical 
issues, data collection method, inclusion and exclusion criteria, instruments used, and 









Chapter 3: Methodology   
The purpose of this study was to address the behavior of primary care physicians 
regarding the prescribing of generic and brand-name drugs for the treatment of chronic 
conditions in the state of North Carolina. The focus of this chapter is on the description of 
the research methodology that was employed for conducting this research. The ethical 
considerations and the limitations posed by the selected research design are described. 
Inclusion and exclusion criteria and the process of recruitment of participants are 
discussed. The process of data collection and the tools used in the collection of data are 
also presented with the justifications for their selection. The method used for the analysis 
of data is discussed, including a discussion of the validity and reliability of the research.  
Design of the Research      
The design of the research provides the process through which a study is 
performed. Therefore, it is imperative to select a design that facilitates the 
accomplishment of the objectives of the research. A quantitative design is represented in 
numbers and statistical methods. Its measurements are numerically based, while its 
findings are used to test a causal hypothesis. This research design is used when the aim of 
the researcher is to perform a large-scale study that involves a baseline survey or an 
assessment of the needs of individuals. This research design does not require the 
participation of the researcher and is autonomous because it can be replicated by any 
person and the results would be the same as that of the primary researcher (Friedhoff et 
al., 2013). Every research design has some advantages and disadvantages, and the 





quantitative research design, including the fact that it can be used for the collection of 
large quantities of data. The results of this design are typically quantifiable because they 
are considered objective. Thus, the data are believed to be quantifiable and they can be 
generalized to a population that is larger. It enables the observation of changes over a 
long period and aids in the development of quantitative indicators (Creswell, 2014). It 
facilitates the provision of distinct, quantitative measures that can be used for proposals 
and grants.  
There are numerous disadvantages of a quantitative research design, including the 
calculation of its results through software used for data analysis (such as SPSS), Access, 
or Excel); quantitative data software might not be accessible in many countries. This 
research design is time consuming because the process is lengthy and it involves the 
entering, cleaning, and analysis of the data by the researcher. The duration of this process 
is prolonged with a larger sample size because a large sample size includes more data that 
requires more time for analysis and interpretation of the results. Furthermore, a large 
sample size also requires more time for the collection of data.  
Therefore, a quantitative research design was used for performing this study, as it 
addressed the objectives of the research. A cross-sectional survey design was employed 
because it involved the use and analysis of the data that are presented in numerical form 
through the employment of statistical techniques. There are several questions that are 
posed by quantitative research, including when, how much, what, how, who, how many, 
and where. The quantitative research method produces data that are statistically reliable 





perceptions of people regarding an issue and their practice of a specific thing. The format 
of quantitative data is typically in numerical form such as ranges, ratios, and averages 
(ACAPS, 2012).  
A qualitative design was not selected due to the constraints posed by the length 
and nature of the study. Use of this design would not have offered the integrity provided 
by the unspecified phenomenon through a quantitative approach.  
The cross-sectional research design is a type of descriptive design that involves 
the collection of data at a specific point in time from a representative population. These 
designs provide information regarding the entire population or subsets of a population 
that has been selected for the research. These are descriptive studies that can be used to 
describe the prevalence of an attitude in the selected group of population (Schmidt, 
2008). This design is used to determine the impact of one variable on other variables. 
Thus, this design is used to analyze the strengths, degree, direction, and magnitude of 
associations. This design enables the emergence of hypotheses that can be further tested 
through experimental and quasi-experimental design. Less cost is involved in this 
research design, and there is a reduced possibility of bias. The information provided 
through this research design is comprehensive, and it describes the variables and the 
pattern of their distribution. This design predicts the association of variables. This design 
does not necessitate waiting for observed outcomes of the research. However, there is a 
possibility of selection bias in this research design because the sample is selected from a 
targeted group of a population which is predefined (Sousa, Driessnack, & Mendes, 2007). 





a population that has been defined. This attribute is present in the population at a 
particular point in time. Contact is made with the participants at a fixed point in this type 
of research design to collect relevant information. Classification of the participants is 
then performed on the basis of this information to identify them as possessing or lacking 
that attribute. In some cases, an attempt of cross-sectional is beyond the limits of 
provision of information on the frequency of the characteristic of interest in the 
population of study through collection of information on both the characteristic of interest 
and latent risk factors. These surveys are also used to assess the attitudes, practices, 
beliefs, and knowledge of a population in association with events pertaining to health. 
The findings of these surveys provide an indication of the extent of a problem in a 
specific population at a particular period in time. The design of apt public health 
measures can also be performed through this research design (Merrill, 2013).   
There are two methods of data collection: primary and secondary. Primary data 
provides access to primary resources, while secondary data offer information that has 
been provided by previous research. Secondary data excludes the possibility of obtaining 
the results that are delivered by the first-hand sources. Primary data is useful because it 
allows the researcher to collect the information directly from the participants. This 
ensures that the data is presented by the actual subject and not an interpretation of the 
results of the original data provided by the participants to another researcher (Little, 
2013).  
Considering the significance of primary data, I selected this source of data. There are 





vary according to the design of the research. This study was performed through a 
quantitative design, and data collection was conducted by a primary data collection 
method.  
Justification for the Selected Research Design  
This study determined the behavior of primary care physicians regarding the 
prescribing of generic and brand-name drugs for the treatment of chronic conditions in 
the state of North Carolina. The design for this research was a cross-sectional design. 
This design was chosen because it addressed the research question of the study regarding 
the influence of brand-name drugs, the therapeutic effects of brand-name medicine, and 
their popularity on physicians’ patterns of prescription of brand-name medications over 
generic medications considering the relative low cost of generic drugs. Through the use 
of a cross-sectional research design, it became possible to predict the factors that are 
responsible for impacting the attitudes of general physicians to prescribe either brand-
name or generic medicine. It facilitated the evaluation of the impact of these factors over 
a specific time period on the behavior of general physicians.   
Ethical Considerations   
It is important to consider ethics prior to the commencement of a study. Ethical 
considerations are a significant aspect of research throughout a study (Burns & Grove, 
2011). The ethics of a study are referred to as the tentative, reasonable, and moral aspects 
of employment of data provided by other researchers in a manner that does not escort its 
manipulation. This phenomenon is associated with the characteristics of conscientious 





must be agreed upon by the researcher when performing a study. Because a quantitative 
design was employed in this study, there were numerous ethical considerations involved 
that needed to be addressed before the commencement of the research.  
Specific Ethical Issues in the Study  
An ethical approval was obtained from the Institutional Review Board to allow 
the researcher to perform this study. Utilization of the information regarding the practices 
of general physicians might be considered sensitive because it may enable the prediction 
of the practices of GPs and the influence on the behavior of patients regarding the use of 
drugs. It is important to ensure the confidentiality of the participants so that their 
identities can be concealed. Therefore, the participants will be asked to accept the terms 
and conditions of the survey that will be mentioned on the online survey site. The 
demographic data provided by the participants will be kept strictly confidential. The 
results of this research will demonstrate the attitudes of GPs regarding the prescription of 
drugs, so there is a chance of professional threats being posed to the GPs participating in 
the research. Additionally, HIPAA issues are also involved in this research because there 
are restrictions imposed by HIPAA related to the access to patient information. This can 
serve as a barrier in obtaining the information from primary care physicians regarding 
their habits in prescription either the brand-name or generic drugs. Therefore, participants 
will sign an informed consent document to allow sharing the healthcare information for 





Confidentiality of the Data   
It will be guaranteed that the information obtained in this research is not utilized 
for any purposes other than for this specific study. The data obtained from this research 
will be kept confidential and protected by keeping all the data in a personal password-
protected laptop to ensure that only the researcher has the access to data. Following the 
completion of research, all the data will be destroyed to minimize the risk of disclosure of 
any confidential data.   
Limitations of the Study    
There are several limitations in this study. The first limitation of this study is the 
limited availability of time for conducting the research as the researcher will be required 
to conduct the surveys in a predetermined period of time. Second, the sample of the study 
will rely only on the population of North Carolina. Therefore, the results of this research 
will be representative of only a specific region and so might not be applicable to the 
entire population of the world. Thus, this study will not be able to address and determine 
the factors responsible for the behavior of physicians regarding the prescription of brand-
name drugs over generic medicines at a global level. The sample size of the study will be 
a limitation since it is too small to represent the habits of all general practitioners 
regarding the prescription of generic and brand-name drugs.   
Another prominent limitation of this research comes from its methods of data 
collection. As mentioned above, the survey will be performed online through an online 
survey site. This can cause difficulties in the analysis of the data, as it will be performed 





should be large enough to provide valid results. Based on this fact, there will be a need 
for further research with a larger sample size to ensure the delivery of valid results.  
Inclusion and Exclusion Criteria    
The inclusion criteria of a study ensures that those participants are recruited that 
are the target population. In the present research the target population is physicians in 
North Carolina mostly because it was convenient for the researcher to contact and 
conduct survey in this specific region. Other regions were not selected for conducting the 
survey because the researcher was interested in determining the prescribing practices of 
general physicians in this area. The parameters of the inclusion and exclusion criteria of 
the primary and secondary research are different. These variations are based on the fact 
that secondary research includes the information that is not provided directly by the 
participants; rather, it is representative of the data provided by the primary data of other 
studies. Therefore, the inclusion criteria of this study include the characteristics of 
primary research method that is based on the recruitment of target population of the 
research.  
The participants of this study will be included based on their relevance to the 
target population of the research (i.e., they must be practicing primary care physicians in 
North Carolina because the object is to determine the prescribing practices of these 
physicians). The researcher will ensure that all the participants prescribe both kinds of 
drugs (generic and brand-name) so that it becomes possible to determine the factors that 
are involved in the practicing attitudes of primary care physicians. Both male and female 





both the genders regarding the prescription of brand-name and generic medications. This 
provides an opportunity to view the differences in the prescribing practices of both 
genders. This enables the collection of cumulative data.  Participants would be required 
to have a clinical practicing experience of at least one year.  
The research question that guides this study is, “what factors influence a 
physician’s pattern of prescription of brand-name medications over generic 
medications?” The hypotheses is  Ho: brand popularity and its therapeutic effect do 
influence prescribing behavior of brand-name medications over generic medications, and 
H1: brand popularity and its therapeutic effect do not influence prescribing behavior of 
brand-name medications over generic medications.  
Data analysis is a vital component of quantitative research. The frequently used 
method for analysis of quantitative data is through statistical analysis. There are various 
factors that determine the manner in which the analysis of data is performed. These 
factors include number of variables that are being examined, the extent of measurement 
of those variables, the utilization of the data for the purpose of inferential or descriptive 
functionality, and ethical responsibilities. As a result, descriptive statistics, correlational 
analysis, and multiple linear regression analysis were utilized for this study using SPSS 
version 23.0. Prescribing generic drugs more frequently can reduce the cost of treatment 
(the dependent variable), while independent variables are therapeutic effects, side effects, 





Sample Size and Process of Sampling  
The sample size of a study is a major consideration because it is the primary 
source of data. Therefore, it is essential to ensure that the size of the sample is adequate 
to provide results that are valid and representative of the views and observations of the 
participants. It is difficult to predetermine the size of the sample because the survey will 
be performed online through an online site that allows only small samples. Therefore, the 
power analysis was applied by getting the list of all practicing physicians in North 
Carolina from the state Board of Examiner’s Registry. Creative Research Systems survey 
software was used for calculating the sample size. It provided a total population of 22,357 
physicians practicing in North Carolina, and with a confidence interval of 5, the sample 
size required for this study was calculated to be approximately 378 participants. A 
logistic regression analysis test of the collected data was performed. 
                                
Figure 1. Power analysis of the sample size by Creative Research Systems survey 
software (2012). 
There are several strategies that can be used for selecting an appropriate and 





sampling. The nonprobability sampling method includes purposive sampling, 
convenience sampling, and snowball sampling, while the probability sampling method 
includes random sampling, stratified, and cluster sampling (Rubin & Babbie, 2009).  
The sampling method used in this study is a purposive sampling method. This is 
based on the fact that the aim of this study is to determine the factors that affect the 
prescribing attitudes of the physicians regarding brand-name and generic drugs. The 
target population of this study is primary care physicians; hence, the researcher will 
ensure that a sampling method is used that assures a valid sample of the target study 
group. Based on these facts, a purposive sampling method was employed to make certain 
that the sample contains only the physicians that are practicing medicine in North 
Carolina.  
Process of Recruitment  
The recruitment process of this study was performed by getting a list of all the 
practicing physicians in North Carolina from the state registry. Obtaining this list allowed 
gathering of the contact details of all those physicians. All the primary care physicians 
were then contacted via telephone and asked to participate in the survey. Contacts were 
made in alphabetical order and all the physicians were called, thus ensuring that they are 
practicing medicine in North Carolina. Physicians were provided brief information about 
the research and if a physician did not show interest in participating, then next physician 
was contacted until a sample of 378 general physicians was recruited. Therefore, the 
sampling of this study was performed through purposive sampling and all the primary 





study. Physicians were guided to the online survey site where the research was being 
conducted. Participants were provided with all necessary information regarding this 
research to make them aware of the purpose and aim of this study. Recruitment was 
based on the desire of participants to take part in the study. All participants willing to 
participate were provided a link to the online survey site and further information about 
the duration of the survey. 
Data Collection   
Data collection in this study was performed through primary methods. Although 
there are several methods of data collection in quantitative primary research, surveys are 
the most common and popular method for the collection of data. This is particularly 
important when information has to be gathered from large groups and it is vital to obtain 
standardization. There are several ways in which a survey can be constructed. Despite the 
manner in which a survey is constructed, two components are always present: questions 
and responses (Fowler, 2009). There has been a change in the process of surveys from the 
days of paper and pencil. Exploration of the various emerging technologies is being 
performed by various evaluators in the healthcare field in order to employ these new 
technologies in the process of research that has led to the use of online surveys for the 
collection of data (Fielding et al., 2008).   
There are numerous factors that determine the selection of an appropriate survey 
method. These factors include availability of resources, complexity of the questions, and 
the schedule of the project. There are several factors that make web-based surveys 





reducing the time and procedures involved in the collection of data and its analysis. 
Secondly, through systematic checks, it becomes possible to block out the responses that 
are out of range (Chaudhuri & Stenger, 2010).  
This research requires the collection of descriptive data, and surveys allow this 
with ease. Limitations of time and resource availability are the constraints of this study 
that can be overcome by the employment of an online survey. Therefore, an online survey 
method was used in this research. It has been predicted that this method will involve 
some issues regarding the quality of data. It will be difficult to determine the actual 
identity of a respondent. Furthermore, it will also be difficult to determine the precision 
of the survey responses. A 40% response rate will be ensured through notifications to the 
participants sent prior to the initiation of the survey. Evidence suggests that online 
surveys usually receive higher response rates in comparison to the traditional methods 
(Burton, Civitano, & Steiner-Grossman, 2012). However, considering the possibility of 
lower response rates, participants were prompted by sending online flyers to motivate 
them to participate in the research. Reminders were also sent to the participants to 
improve the response rates (Nair, 2013).  
Instruments Used  
Instruments used for the collection of data appropriate for gathering the data. 
There are several instruments that are employed in the data collection process in primary 
quantitative research. An online survey was used for the collection of data for this study, 
via the SurveyMonkey Web site. It is Web site that allows creation of online surveys on a 





studies such as Omojasola et al. (2012), El-Dahiyat and Kayyali (2013), and Alghasham 
(2009). The questionnaire was based on both open-ended and closed-ended questions and 
on the nature of the question being asked. Demographic data were obtained through a 
demographic questionnaire that included name, age, and clinical practice experience of 
the participants. The questions used a Likert-type scale with five possible responses: 
strongly agree, agree, disagree, and strongly disagree, and neutral. The variables 
included:  low-cost, popularity, therapeutic effect, effectiveness, quality, preference, and 
side effects. This type of questionnaire enabled me to gather the data regarding the 
behaviors and attitudes of the physicians regarding the prescribing of generic and brand-
name drugs in their practices. The various factors that lead to this behavior were explored 
and determined in a descriptive and numerical form through the utilization of this kind of 
questionnaire. Thus, the researcher was able to statistically analyze the data in a concise 
manner. This questionnaire allowed collecting the data in a more descriptive form that 
facilitated the development of increased understanding of the topic. The questions in the 
questionnaire were based on the medical home model because they determined the 
association of the reduced cost of generic drugs to be related with the prescribing 
practices of the physicians. The concept of the medical home model is based on the 
availability and provision of medicine to all the patients depending on their needs and 
financial condition. The prescribing practices of primary care physicians related to the 
low cost of generic drugs can predict the application of the medical home model in the 





generic drugs to patients with less financial resources, based on the demands of the 
patients themselves.  
Validity is referred to as the accuracy or truthfulness of the measurement as 
intended. The study was performed over a short duration that facilitated the exclusion of 
the influence of history and maturation. The effect of experimental mortality was not a 
factor in this research as it was based on a survey instead of an experiment. The threat of 
testing and instrumentation was not an issue because the questionnaire was adapted from 
a previous study (Omojasola et al., 2012). Reliability is based on the consistency of the 
procedures involved in the research to deliver the results. It is also associated with the 
extent to which research findings can be repeated or reproduced under similar settings 
(Ayodele, 2010).  Cronbach’s alpha was utilized further for ensuring the reliability of the 
instrument by assuring that its value was .80. Furthermore, the collection of responses 
from all the respondents through the same questionnaire and the possibility of utilization 
of the questionnaire elsewhere ensure the repeatability of this study. Therefore, the 
findings of this research are both valid and reliable. The reliability score of the developed 
questionnaire was calculated with the help of SPSS and was found to be .89 for the 10-
item measure. This helps determine that the samples selected were valid and the 
instrument is reliable. 
Analysis of the Data   
Data analysis is a vital component of quantitative research. A frequently used 
method for analysis of quantitative data is statistical analysis. There are various factors 





include the quantity of variables that are being examined, the extent of measurement of 
the variables, the utilization of the data for the purpose of inferential or descriptive 
functionality, and ethical responsibilities.  
The data from this study was analyzed statistically. SPSS version 23.0 was 
utilized for this purpose. Descriptive statistics of the responses collected from the 
participants were analyzed. This method determined the percentages and frequencies for 
the participants’ demographic data and prescribing practices. Statistical tests applied 
included logistic regression analysis of the prescribing practices of participants. This test 
was based on the dependent and independent variables of the study.  
Summary   
Data analysis is a vital component of quantitative research. A frequently used 
method for analysis of quantitative data is statistical analysis. There are various factors 
that determine the manner in which analysis of data is performed. These factors include 
quantity of variables that are being examined, the extent of measurement of variables, the 
utilization of the data for the purpose of inferential or descriptive functionality and ethical 
responsibilities. The data of this research was analyzed statistically. Chapter 4 of this 
study focuses on data analysis, participants’ demographics, analysis of the survey 




















Chapter 4: Analysis and Discussion   
Introduction   
The purpose of this research was to explore physicians’ patterns of prescription of 
brand-name drugs over generic drugs. The research question for this study was the 
following: What factors influence physicians’ pattern of prescription of brand-name 
medications and generic medications? 
 These perspectives included the responsibilities and attitudes of physicians in 
their prescription patterns. North Carolina is striving to supply premium healthcare 
services in a period of inadequate resources, which generated the need for increased use 
of generic medications because generic medication is lower in cost compared to branded 
drugs. Data were analyzed using SPSS version 23. 
The intended sample size for this study was 378; however, the participants’ 
response rate was 40% and only 151 participants completed the research study. To help 
increase the return rate so as to increase the small sample size, the following techniques 
were used: survey repetitions, changing email subject lines, pipping, and e-mail 
notifications. Participants were male and female. In this chapter, I describe the 
participants’ demographics including age, gender, ethnicity, qualification, clinical 
practice, and clinical practice setting. This is followed by a presentation of the findings 
from the analysis of the questionnaire analysis, which included correlations and 





Participant Demographic Characteristics   
Participants from varied demographic backgrounds completed the research study 
and their following characteristics are described: gender, age, education, race and 
ethnicity, clinical practice, and clinical practice setting. There were 151 participants. Age 
in years ranged from 20 to 47 with a mean age of 30.12 (SD = 6.25). As seen in Table 1, 
67 participants were female and 87 were male, and the proportions of male were higher 
than the female in this survey. According to the survey respondents, 51 respondents are 
postgraduate who practice medicines, and 100 respondents have MD degree in 
medicines. In the demographic data, there is one table that relate to clinical practice.  
Fifty four respondents were primary physicians practices; while 97 were doing 
medical practice. With respect to clinical practice setting, the chart and table illustrate 
that clinical practice setting is based on office setting, as described by the 55 respondents. 
On the other hand, 33 respondents; stated that hospital setting is imperative, and 63 





Table 1: Frequency and Percentages of Participant Demographic Characteristics 
Demographic Characteristics n % 
Education Level   
High School 0 3.1 
Some College 0 9.2 
College Graduate 0 33.8 
Graduate School 0 50.8 
Post Graduate 51 1.5 
Master Degree in Medicine 100 1.5 
Total 151       
Race & Ethnicity   
   
African American 23 4.6 
Asian/Pacific Islander 34 4.6 
Hispanic 29 3.1 
Caucasian 64 1.5 
Other 1 1.5 
Total 151 100.0 
Clinical Practice   
Primary Physician 54 83.1 
Medical practice 97 7.7 
Total 151 100.0 
Clinical Practice Setting   
Hospital setting 33 4.6 
Long term facility 63 35.4 
Office/clinical setting 55 60.0 





Analysis of the Questionnaire  
This section of the study focus on the outcome of the questionnaire that was 
returned from the survey participants 
Item number 1: Generic Drugs and Therapeutic Effect. The focus of the first 
survey question questionnaire was on physician perception of generic drug ability to 
produce a therapeutic effect. As seen in Table 2, around 59% (n = 89) of respondents 
strongly agreed that generic drugs are able to produce a therapeutic effect. On the other 
hand, 7.3% (n = 11) strongly disagreed that generic drugs are able to produce therapeutic 
effect.  
Table 2: Frequency and Percentages of Responses for Survey Question 1 
Generic drugs are able to produce therapeutic effect. n % 
Strongly Disagree 11 7.3 
Disagree 13 8.6 
Neutral 11 7.3 
Agree 27 17.9 
Strongly Agree 89 58.9 
Total 151 100.0 
 
Item Number 2: Side Effects – Generic Drugs and Branded Drugs. As seen in 
Table 3, about 60% (n = 91) respondents strongly agree that generic drugs cause more 
side effects than branded drugs. On the other hand, only 6.6% (n = 10) of respondents 





Table 3: Frequency and Percentages of Responses for Question 2 
Generic drugs cause more side effects than brand drugs. n % 
Strongly Disagree 10 6.6 
Disagree 14 9.3 
Neutral 13 8.6 
Agree 23 15.2 
Strongly Agree 91 60.3 
Total 151 100 
 
Item Number 3: Lack of Quality Check on Generic Drugs. About 24% (n = 
36) of respondents strongly agreed that there is lack of quality check on generic drugs 
(see Table 4). On the other hand, 10% (n = 15) of respondents strongly disagreed that 
there is a lack of quality check on generic drugs.  
Table 4: Frequency and Percentages of Responses for Question 3 
There is a lack of quality check on generic drugs. n % 
Strongly Disagree 15 10 
Disagree 36 24 
Neutral 17 11 
Agree 47 31 
Strongly Agree 36 24 






Item Number 4: Low Cost Generic Drugs. As seen in Table 5, 30% (n = 45) of 
respondents strongly agreed that generic drugs have low cost when compared to branded 
drugs. On the other hand, 16% (n = 24) of respondents strongly disagree that cost of 
generic drugs is lower than branded drugs.  
Table 5: Frequency and Percentages of Responses for Question 4 
Generic drugs have low-cost. n % 
Strongly Disagree 24 16 
Disagree 15 10 
Neutral 4 3 
Agree 63 42 
Strongly Agree 45 30 
Total 151 100 
 
Item Number 5: Popularity – Generic VS Branded Drugs. According to Table 
6, 23% (n = 35) of respondents agreed that generic drugs are not as popular as branded 
drugs. On the other hand, 20% (n = 30) of respondents disagree that generic drugs are not 












Table 6: Frequency and Percentages of Responses for Question 5 
Generic drugs are not as popular as brand drugs. n % 
Strongly Disagree 20 13 
Disagree 30 20 
Neutral 28 19 
Agree 38 25 
Strongly Agree 35 23 
Total 151 100 
 
Item Number 6: Representatives - Generic VS Branded Drugs. As seen in 
Table 7, 14% (n = 21) of respondents strongly agree that representatives of branded drugs 
are more convincing than the representatives of generic drugs. Conversely, 17% (n = 25) 
of respondents disagree that representatives of branded drugs are more convincing than 
the representatives of generic drugs.  
Table 7: Frequency and Percentages of Responses for Question 6 
Representatives of brand drugs are more convincing than 
representatives of generic drugs. 
n % 
Strongly Disagree 25 17 
Disagree 36 24 





Agree 49 32 
Strongly Agree 21 14 
Total 151 100 
 
Item Number 7: Prescription of Branded Drugs. The focus of this part of the 
research questionnaire is on patients preferences with respect to branded drugs. As seen 
in Table 8, 17% (n = 26) of respondents strongly disagreed that patients do not prefer to 
be prescribed a branded drugs. On the other hand, 35% (n = 53) respondents strongly 
agreed that patients prefer to be prescribed a branded drug.  
Table 8: Frequency and Percentages of Responses for Question 7 
Patients prefer to be prescribed a brand drug. n % 
Strongly Disagree 26 17 
Disagree 28 19 
Neutral 5 3 
Agree 39 26 
Strongly Agree 53 35 
Total 151 100 
 
Item Number 8: Quality - Generic VS Branded Drugs. 16 % (n = 24) 
respondents strongly disagreed that generic drugs are not equal in quality as brand drugs 
(see Table 9). Conversely, 28% (n = 42) of respondents strongly agreed that generic 







Table 9: Frequency and Percentages of Responses for Question 8 
Generic drugs are equal in quality as brand name 
prescription drugs. 
n % 
Strongly Disagree 24 16 
Disagree 19 13 
Neutral 23 15 
Agree 43 28 
Strongly Agree 42 28 
Total 151 100 
 
 
Item Number 9: Safety - Generic VS Branded Drugs. With respect to safety of 
generic drugs, 36% (n = 55) of the respondents strongly agreed that generic drugs are 
safer than branded drugs, (see Table 10). On the other hand, 14% (n = 21) of the 






Table 10: Frequency and Percentages of Responses for Question 9 
Generic drugs are as safe as brand name prescription 
drugs. 
n % 
Strongly Disagree 21 14 
Disagree 28 19 
Neutral 4 3 
Agree 43 28 
Strongly Agree 55 36 
Total 151 100 
 
Item Number 10: Inferiority - Generic Versus Branded Drugs. About 28% (n 
= 43) respondents strongly agree that generic drugs are inferior in quality than branded 
drug (see Table 11). On the other hand, 23% (n = 35) of respondents strongly disagree 
that generic drugs are inferior to branded drugs.  
Table 11: Frequency and Percentages of Responses for Question 10 
Generic drugs are inferior to brand name prescription 
drugs. 
n % 
Strongly Disagree 35 23 
Disagree 24 16 
Neutral 10 7 
Agree 39 26 





Total 151 100 
 
Item Number 11: Patent Expiry of Originator/Innovator. According to 24% 
(n = 35) of the respondents, generic drugs are not manufactured after the patent expiry of 
originator or innovator (see Table 12). Conversely, 33% (n = 50) of the respondents 
strongly agreed that generic drugs are manufactured after the patent expiry of originator 
or innovator.  
Table 12: Frequency and Percentages of Responses for Question 11 
Generic medicines are manufactured after the patent 
expiry of originator/innovator. 
n % 
Strongly Disagree 19 13 
Disagree 16 11 
Neutral 23 15 
Agree 43 28 
Strongly Agree 50 33 
Total 151 100 
 
Item Number 12: Low Quality - Generic VS Branded Drugs. 21 % (n = 32) of 
respondents strongly disagree that generic drugs are of low quality than branded drugs 
(see Table 13). Conversely, 29% (n = 44) respondents strongly agree that generic drugs 






Table 13: Frequency and Percentages of Responses for Question 12 
Generic medicines are of low quality than brand name 
medicines. 
n % 
Strongly Disagree 32 21 
Disagree 18 12 
Neutral 14 9 
Agree 43 28 
Strongly Agree 44 29 
Total 151 100 
 
Item Number 13: Multinational Product VS Local Product. According to 
Table 14, 32% (n = 49) of the respondents, multinational products are of better quality 
than local company’s product. Conversely, 16% (n = 24) of respondents strongly disagree 
that multinational products are of better quality than local company’s product.  
Table 14: Frequency and Percentages of Responses for Question 13 
Multinational products are of better quality than local 
company products. 
n % 
Strongly Disagree 24 16 
Disagree 21 14 
Neutral 14 9 
Agree 43 28 





Total 151 100 
 
Item Number 14: Remembrance of Brand Name Medicine. According to 
Table 15, 12% (n = 18) of respondents strongly disagree that it is not easier to remember 
the name of branded drugs; while, 30% (n = 45) of respondents strongly agreed that it is 
easier to remember the name of branded drugs. 
Table 15: Frequency and Percentages of Responses for Question 14 
It is easier to remember a brand name medicine. n % 
Strongly Disagree 18 12 
Disagree 24 16 
Neutral 20 13 
Agree 44 29 
Strongly Agree 45 30 
Total 151 100 
 
Item Number 15: Affordability - Generic VS Branded Drugs. From 151 
respondents, 34% (n = 52) of respondents strongly agree that generic drugs are more 
affordable as compare to branded drugs (see Table 16). On the other hand, 9% (n = 14) of 
respondents strongly disagree that generic drugs are more affordable as compare to 







Table 16: Frequency and Percentages of Responses for Question 15 
Generic medicines are more affordable as compared to brand 
medications. 
n % 
Strongly Disagree 14 9 
Disagree 18 12 
Neutral 24 16 
Agree 43 28 
Strongly Agree 52 34 
Total 151 100 
 
Item Number 16: Preferences of Patients. According to Table 17, 41% (n = 62) 
of respondents strongly agreed that patients mostly prefer branded drugs; while only 9% 
(n = 14) of respondents strongly disagreed that patient do prefer branded drugs 
Table 17: Frequency and Percentages of Responses for Question 16 
Patients prefer brand medications. n % 
Strongly Disagree 14 9 
Disagree 18 12 
Neutral 14 9 
Agree 43 28 
Strongly Agree 62 41 






Item Number 17: FDA and Brand Medications. As seen in Table 18, 26% (n = 
40) of respondents strongly agreed that prescription of branded drugs is good for the 
health of patients as compare to generic drugs because they are approved by the FDA. 
Conversely, 16 % (n = 24) of respondents strongly disagreed that prescribing brand drugs 
is good for the patient because they are approved by the FDA. 
Table 18: Frequency and Percentages of Responses for Question 17 
Prescribing brand medications feel safe because they are 
approved by the FDA. 
n % 
Strongly Disagree 24 16 
Disagree 28 19 
Neutral 14 9 
Agree 45 30 
Strongly Agree 40 26 
Total 151 100 
 
Item Number 18: Option to Choose for the Medications. According to Table 
19, 32% (n = 48) of respondents, patients should be given the option to choose for the 
medication that is affordable to them. Conversely, 21 % (n = 32) of respondents strongly 
disagree that patients should be given the option to choose for the medication that is 







Table 19: Frequency and Percentages of Responses for Question 18 
Patients should be given the option to choose for the 
medication that is affordable to them. 
n % 
Strongly Disagree 32 21 
Disagree 24 16 
Neutral 10 7 
Agree 37 25 
Strongly Agree 48 32 
Total 151 100 
 
Item Number 19: Quality of Expensive Medications. According to Table 20, 
33% (n = 50) of respondents, expensive medications are considered to be better and more 
effective by the patient. Conversely, 12% of respondents state that expensive medications 
are not considered to be better and more effective by the patient. 
Table 20: Frequency and Percentages of Responses for Question 19 
Expensive medications are considered better and more 
effective by the patients. 
n % 
Strongly Disagree 18 12 
Disagree 16 11 
Neutral 24 16 
Agree 43 28 





Total 151 100 
 
The following six questions and their relationships were further explored using 
descriptive statistics, correlational analysis and multiple linear regression: (a) generic 
drug are unable to produce therapeutic effects, (b) do patient prefer brand name drug to 
generic drugs, (c) generic drug cause more side-effects than brand name drugs, (d) 
generic drug have lower cost compare to brand drugs, and (e) more of generic prescribing 
can reduce cost of treatment. 
Descriptive Statistics   
The descriptive statistics for these variables appear in Table 21. Responses for 
generic drugs are unable to produce therapeutic effects ranged from 1 (strongly disagree) 
to 5 (strongly agree) with a mean of 4.12 (SD = 1.28). This indicates that, on average, 
participants agreed that generic drugs are unable to produce therapeutic effects. 
Responses for do patients prefer brand name drugs to generic drugs ranged from 1 
(strongly disagree) to 5 (strongly agree) with a mean of 4.13 (SD = 1.28). This indicates 
that, on average, participants agreed that patients prefer brand name drugs to generic 
drugs. Responses for generic drugs cause more side-effects than brand name drugs 
ranged from 1 (strongly disagree) to 5 (strongly agree) with a mean of 3.61 (SD = 1.52). 
This indicates that, on average, participants were neutral or agreed that generic drugs 
cause more side-effects than brand name drugs. Responses for generic drugs have lower 
cost compare to brand drugs ranged from 1 (strongly disagree) to 5 (strongly agree) with 





generic drugs have lower cost compare to brand drugs. Finally, responses for more 
generic prescribing can reduce cost of treatment ranged from 1 (strongly disagree) to 5 
(strongly agree) with a mean of 4.32. On average, participants agreed that more generic 
prescribing can reduce cost of treatment. 
Table 21: Descriptive Statistics for Primary Survey Questions (N = 151) 
Survey Item Min Max M SD 
Generic drugs are unable to produce therapeutic effects 1.0 5.0 4.12 1.28 
Do patients prefer brand name drugs to generic drugs 1.0 5.0 4.13 1.28 
Generic drugs cause more side-effects than brand name 
drugs 
1.0 5.0 3.61 1.52 
Generic drugs have lower cost compared to brand drugs 1.0 5.0 4.32 1.26 
More generic prescribing can reduce cost of treatment 1.0 5.0 3.06 1.45 
 
Correlation   
Pearson correlations were used to assess the bivariate relationships between the 
five primary variables: (a) generic drugs are unable to produce therapeutic effects, (b) do 
patient prefer brand name drugs to generic drugs, (c) generic drugs cause more side-
effects than brand name drugs, (d) generic drugs have lower cost compared to brand 
drugs, and (e) more generic prescribing can reduce cost of treatment. It is important to 
note that correlations are used to examine the relationship between only two variables at a 








Table 22: Pearson Correlations between the Variables (N = 151) 
Survey item 1 2 3 4 5 
1. Generic drug are unable to produce therapeutic 
effects 
r 1     
2. Do patients prefer brand name drug to generic drugs r .07 1    
p .36     
3. Generic drugs cause more side-effects than brand 
name drugs 
r .18* -.07 1   
p .02 .37    
4. Generic drugs have lower cost compared to brand 
drugs 
r .02 -.07 -.07 1  
p .73 .35 .35   
5. More generic prescribing can reduce cost of 
treatment 
r -.01 .03 -.06 .07 1 
p .85 .64 .43 .33  
Note. * indicates p < .05. 
 
Correlations with generic drugs are unable to produce therapeutic effects. As 
seen in Table 22, there was a small, positive, statistically significant correlation between 
generic drugs are unable to produce therapeutic effects and generic drugs cause more 
side-effects than brand name drugs (r = .18, p = .02). This indicates that as agreement 
that generic drugs are unable to produce therapeutic effects increases, agreement that 





drugs are unable to produce therapeutic effects was not significantly correlated with any 
of the other variables. 
Correlations with do patients prefer brand name drugs to generic drugs. As 
seen in Table 22, there were no statistically significant correlations between do patients 
prefer brand name drug to generic drugs and the other four variables.   
Correlations with generic drugs cause more side-effects than brand name 
drugs. As previously noted, there was a small, positive, statistically significant 
correlation between generic drugs cause more side-effects than brand name drugs and 
generic drugs are unable to produce therapeutic effects (r = .18, p = .02). There were no 
other statistically significant correlations between generic drugs cause more side-effects 
than brand name drugs and the remaining three variables (see Table 22).   
Correlations with generic drug have lower cost compared to brand drugs. As 
seen in Table 22, there were no statistically significant correlations between generic 
drugs have lower cost compared to brand drugs and the other four variables.   
Correlations with more generic prescribing can reduce cost of treatment. As 
seen in Table 22, there were no statistically significant correlations between more generic 
prescribing can reduce cost of treatment and the other four variables.   
Regression Analysis    
A simultaneous multiple linear regression analysis was used to explore the 
relationship between (a) generic drug are unable to produce therapeutic effects, (b) do 
patients prefer brand name drug to generic drugs, (c) generic drugs cause more side-





(the independent variable) and (e) more generic prescribing can reduce cost of treatment 
(the dependent variable). 
As seen in Table 23, the model was not statistically significant (F(4, 146) = 0.41, 
p = .79) and accounted for only 1.1% of the variance in perceptions that more generic 
prescribing can reduce cost of treatment.  
Table 23: ANOVA for the Relationship between The Independent Variables and More of 
Generic Prescribing can Reduce Cost of Treatment (The Dependent Variable) 
Model 
Sum of 
Squares df Mean Square F p 
1 Regression 3.55 4 0.88 0.41 .79 
Residual 313.78 146 2.14   
Total 317.33 150    
 
The Tolerance, and the Variance Inflation Factor were examined. Per Cohen, 
Aiken, and West (2004), the results indicated that multicollinearity was not an issue 
given that Tolerance values were above .10 and VIF values were less than 10. Given the 
lack of a statistically significant regression model, the regression coefficients in Table 24 
were not interpreted. The null hypothesis that there will not be a statistically significant 
predictive relationship between (a) generic drug are unable to produce therapeutic effects, 
(b) do patients prefer brand name drug to generic drugs, (c) generic drugs cause more 





drugs (the independent variable) and (e) more generic prescribing can reduce cost of 
treatment (the dependent variable) was accepted. 
 
Table 24: Regression Coefficients for the Relationship between The Independent 
Variables and More Generic Prescribing can Reduce Cost of Treatment (The Dependent 
Variable) 
Model B Std. 
Error 
β t p Tol. VIF 
Generic drugs are unable to produce 
therapeutic effects 
-.01 .09 -.01 -.12 .90 .95 1.04 
Do patients prefer brand name drugs 
to generic drugs 
.04 .09 .04 .49 .62 .97 1.02 
Generic drugs cause more side-effects 
than brand name drugs 
-.05 .08 -.05 -.62 .53 .94 1.05 
Generic drugs have lower cost 
compared to brand drugs 
.09 .09 .07 .94 .34 .98 1.01 
 
Linearity Test Summary   
Based on Table 25, the Deviation from Linearity value of 1.198 was not 
statistically significant (p > .05). Thus, there is a linear relationship between the variables 
























(Combined) 7.696 4 1.924 .907 .462 




7.623 3 2.541 1.198 .313 
Within Groups 309.641 146 2.121   
Total 








Based on Table 26, the Deviation from Linearity value of 0.592 was not 
statistically significant (p > .05). Thus, there is a linear relationship between the variables 
BRANDEDDRUG and PHYPRESCRIPTION. 






Square F Sig. 
More generic 
prescribing can 
reduce cost of 







(Combined) 4.266 4 1.066 .497 .738 
Linearity .461 1 .461 .215 .644 
Deviation 
from Linearity 
3.805 3 1.268 .592 .622 
Within Groups 313.072 146 2.144   
Total 











 Based on Table 27, the Deviation from Linearity value of 1.587 was not 
statistically significant (p > .05). Thus, there is a linear relationship between the variables 
PERCEPTION and PHYPRESCRIPTION. 






Square F Sig. 
More generic 
prescribing can 









(Combined) 11.263 4 2.816 1.343 .257 
Linearity 1.280 1 1.280 .611 .436 
Deviation 
from Linearity 
9.983 3 3.328 1.587 .195 
Within Groups 306.075 146 2.096   
Total 







Based on Table 28, the Deviation from Linearity value of 0.320 was not 
statistically significant (p > .05). Thus, there is a linear relationship between the variables 
GENMEDICATION and PHYPRESCRIPTION. 






Square F Sig. 
More generic 
prescribing can 
reduce cost of 
treatment * 
Generic drugs 





(Combined) 4.025 4 1.006 .469 .759 
Linearity 1.963 1 1.963 .915 .340 
Deviation 
from Linearity 
2.062 3 .687 .320 .811 
Within Groups 313.313 146 2.146   
Total 
317.338 150    
. 
In Tables 25 through 28, a summary of linearity test was conducted to check for 
model violation, the analysis shows that there was no violation as such the model use is 
appropriate for this study. 
Summary   
 The focus of the study was to determine the primary care physicians’ perspectives 





included the responsibilities and attitudes of physicians who prescribe medications to 
their patients. The state of North Carolina is striving to supply premium healthcare 
services in a period of inadequate resources. This generated the need for increased use of 
generic medication due to its lower cost when compared to branded drugs. This chapter 
included a descriptive analysis of 19 survey questions and the examination of the 
bivariate and multivariate relationship between five key variables. All data were analyzed 
in SPSS version 23.  
 Bivariate analysis using Pearson correlation showed that there was a small, 
positive, statistically significant correlation between “generic drugs are unable to produce 
therapeutic effects” and “generic drugs cause more side-effects than brand-name drugs” 
(r = .18, p = .02). As agreement that generic drugs are unable to produce therapeutic 
effects increases, agreement that generic drugs cause more side-effects than brand-name 
drugs also increases. There were no other statistically significant correlations between (a) 
generic drugs are unable to produce therapeutic effects, (b) do patients prefer brand-name 
drugs to generic drugs, (c) generic drugs cause more side-effects than brand-name drugs, 
(d) generic drugs have lower cost compared to brand-name drugs, and (e) more generic 
prescribing can reduce the cost of treatment. 
Multivariate analysis using multiple linear regression showed that there was not a 
statistically significant predictive relationship between (a) generic drugs are unable to 
produce therapeutic effects, (b) do patients prefer brand-name drug to generic drugs, (c) 
generic drugs cause more side-effects than brand-name drugs, (d) generic drugs have 





generic prescribing can reduce the cost of treatment (the dependent variable). As such, 






















Chapter 5: Recommendations, Implications, and Conclusion    
This chapter provides discussions on recommendations, study implications, study 
limitations, and conclusions of the study. 
Key Recommendations   
Stakeholders  
Although current picture of the U.S. health-insurance market is uncertain, 
enrollment can be anticipated in terms of demographics so there is a need for insurance 
providers, policy makers, and other healthcare providers to look for innovative ways to 
bring down the cost of prescription drugs.  
Legal Framework  
The state is responsible for creating reliable distribution channels that can provide 
easy access to the insurance market. This can be accomplished through necessary 
legislative, regulatory, and business policies, and it must comply with both state and 
federal regulations. Consumers of insurance should be thoroughly informed about 
services available, and must be taught in language that they understand.  Finally, federal 
agencies should monitor premium trends of insurance firms 
Healthcare Insurance Plans  
Commercial insurance plans should be prepared by marketing experts with the 
help of innovative tools so that cost can be decreased and consumers have more choices 
for selecting different providers. These innovative tools should include social media sites, 
mobile applications, and print media for interacting with the consumers. Strategies should 





like alternative medicines. Finally, better commercial insurance plans should include 
reduced operational costs and increased consumer baselines.  
Hospitals and Healthcare Professionals  
Providers must manage the demands and visit resources, encourage hospitals to 
provide quality healthcare at less cost through coordination. Organizational structure and 
revenue analysis should be done for checking the accountability of the operations such as 
collections and facilities provision records. Providers should obtain the maximum 
possible information about the consumer to avoid potential bad debts, and patient 
networking should be present in the insurance market 
Employers  
Employers should consider the incorporation of healthcare insurance as a value-
added package for their employees, should analyze the availability of better tools that 
provide better potential outcomes, and provide flexibility to employees for choosing a 
healthcare plan of their own choice. Finally, IT companies should obtain accurate data for 
enrollment and determine ways for enhancing trends. 
Consumers/Patients   
Consumers must participate in insurance retailing by selecting the insurance plan 
of their own choice through a better decision-making process. This can ultimately 
transfer the pressure to the insurance sector for providing potential benefits within the 
lowest-cost method of operations. The design of insurance plans should consider the risk 





Study Implications   
The positive social change implication of the results of this study is such that it 
would help to appropriately and optimally utilize resources by educating patients and 
healthcare services providers in regard to the use of generic drugs so as to minimize cost 
without compromising efficacy, and informing policy makers regarding the same. 
Study Limitations   
There are several limitations associated with this study. First, there was not 
enough time for conducting the research as I was required to conduct the surveys in a 
predetermined period of time. Second, the sample of the study only included the 
population of North Carolina. Therefore, the results of this research will be representative 
of only a specific region and might not be applicable to the entire population of the 
United States. Sample size of the study is also a limitation because it is too small to 
present the practices of all the general practitioners regarding the prescription of generic 
and brand-name drugs. Another important limitation of this research was the method of 
data collection. An online survey approach was used, and this method may not produce a 
large enough sample size. This can cause difficulties in the analysis of the data, if such 
analysis is performed statistically. Quantitative studies using the statistical analysis 
method require a large sample size to provide valid results. Based on this fact, there will 






Conclusion   
I concluded that in the absence of national health insurance, people are dependent 
only on self-sponsored insurance and pay their expenses out of pocket. The cost is 
increasing without making changes in the effectiveness of medication whether generic or 
brand-name drug. Thus, it forces the healthcare professionals to exclude the insurance 
benefits from the patients. The number of uninsured patients is still high and may 
increase due to the high level of premium contributions. Due to increased healthcare 
costs, the future growth of the sector is subjected to potential threats. Based on such 
consequences, most healthcare professionals suggest generic medicines to their patients 
because these drugs are cost effective.  
Increased premium contributions force enrollees to switch from one plan to 
another. Thus, controlling sharp swings in premiums is necessary. A law such as the 
“America’s Healthy Futures Act of 2009,” although it includes insurance standards, does 
not support a public healthcare plan. Furthermore, the inadequate knowledge, along with 
the attitudes and perceptions of primary care physicians are minimizing the outcomes that 
confuse the patients about their medication choices; for instance, generic over brand-
name drugs.  
The standard criteria for medical interventions include assessment, classification, 
planning, and education. The assessment for determining the usage can be done by 
various methods by evaluating through discussion, physical evaluation, reviewing of 
medication, and psychosocial as well as environmental analyses. The medication 





illnesses such as pain management in older patients. For instance, it can be done by using 
an acronym such as “OPQRSTU” in which the letter “O” stands for Onset: it defines the 
beginning time of pain. “P” stands for Provoking: what factors make pain conditions 
better or worse. “Q” represents Quality: the feeling when the pain is occurring. “R” is for 
Region/Radiation, and defines the exact location of pain. “S” indicates Severity, and it 
defines the extent of the pain. “T” stands for Treatment, which establishes which 
medications are currently being used, what is their effectiveness, are there any side 
effects, and an examination of past medications records. The letter “U” denotes 
Understanding the factors that are responsible for the pain and how the pain affects the 
patient and family. “V” is for Values, and it defines the program in order to manage the 
pain by considering all factors and this aspect involves a physical assessment. 
The healthcare system of the United States is established on the idea that healthy 
lives leads to healthy people. This is the overall strategy of the government and there is 
an increasing shifting of strategies because the US is facing the key challenges of non-
communicable diseases, while sexually transmitted diseases are becoming more common 
and a large portion of the population engages in alcohol consumption and smoking. 
Furthermore, the mental health issue among young people and confusing conclusions 
given by the doctor also create issues that sometimes results the patient’s death or loss of 
function. Another bitter fact is the inequalities among poor and rich in terms of medical 
treatments since 85% of the population uses public healthcare facilities, which are less 





the dilemma and it could not be solved easily just by giving health education to the 
people of US (Petersen et al., 2005). 
Teaching people in the US to appreciate the benefits that technology can bring for 
their health is portrayed as advantageous, even although it may not prevent issues about 
restrictions on the make use of ICT as “e-health” can enhance medical facilities. Health is 
a major concern for the US government and broad planning gives a structure for the 
improvement of the national healthcare system. The scheme gives the chance to 
collectively bring the resources of the country, intercontinental expansion, commerce and 
savings policies that influence the national healthcare administrative system. The 
conclusion should be a scheme that is challenging and attainable, that will get better 
wellbeing and welfare in the United States, and permit the government to report facts 
about healthcare system (Lehrman, 2005).  
The government of US should be clear about the mandate of the World Health 
Organization (WHO) and other multinational agencies that can promote and encourage 
healthcare systems effectively. The inputs of the domestic government and agencies 
should be also countable in order to consider human rights with respect to promoting 
healthcare facilities. Moreover, this should also include protection of a safe water supply 
with adequate sanitary conditions in communities as well as at work places in order to 
achieve good physical health. Moreover, mental health can be beneficial for the progress 
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Appendix: Instruments   
INSTRUCTIONS: 





Survey Questionnaire  
Part A: Perceptions about Generic and Brand name Drugs  
Please place an "X" in the box to your right to the following comments below: 
 Strongly 
Agree 
Agree Neutral Disagree Strongly 
Disagree 
Generic drugs are unable to 
produce therapeutic effect? 
   
 
  
Generic drugs cause more side 
effects than Brand drugs: 
 
 
    
There is a lack of quality check 
on generic drugs:   
 
 
    
Generic drugs have low-cost:  
 
    
Generic drugs are not as popular 
as brand drugs:    
 
 
    
Representatives of brand drugs 
are more convincing than 
representatives of generic drugs:     
 
 
    




    
Generic drugs are equal in quality 
as brand name prescription drugs:   
 
 
    
Generic drugs are as safe as brand 
name prescription drugs: 
 
 
    
Generic drugs are as effective as 
brand name prescription drugs: 
 
     
Generic drugs are inferior to 
brand name prescription drugs:   
 
     
Generic medicines are 
manufactured after the patent 
expiry of originator/innovator: 
 
     
Generic medicines are of low 
quality than brand name 
medicines: 
 
     
Multinational products are of 
better quality than local company 
products 
 












Agree Neutral Disagree Strongly 
Disagree 
It is easier to remember a brand 
name medicine: 
   
 
  
Knowledge about cost of 




    
Generic medicines are more 




    
Medical representativeness 
influences prescribing practices: 
 
 
    
Patients prefer brand medications:     
 
    
Generic drugs generally produce 
the indented therapeutic effects:    
 
 
    
Prescribing brand medications 
feel safe because they are 
approved by the FDA: 
 
 
    
Generic drug prescribing can 
reduce the cost of treatment:    
 
 
    
Patients should be asked about 
their preference prior to 
prescription of medication: 
 
 
    
Patients should be given the 
option to choose for the 




    
Generic medicines should only be 
prescribed on the request of 
patients:   
     
Patients prefer brand medications: 
 
     
Expensive medications are 
considered better and more 
effective by the patients: 
 
     
  
 









Race & Ethnicity:  
Level of Education: 
Clinical Practice: 
Clinical Practice Setting:  
 
 
Thank you for your time in completing this survey 
